HOME     SUBSCRIBERS     TRADE     PRODUCTS & SERVICES    
About Sharenet
Enter any share name or code:    

08-Nov-2018
(Official Notice)
In terms of the JSE Limited Listings Requirements, a listed company is required to advise shareholders once it receives notice of any change in its external auditors. NUT hereby advises shareholders that the Company?s external auditors, Grant Thornton have joined SizweNtsalubaGobodo, who are now called SNG Grant Thornton, with immediate effect. Mr EY Lakhi will remain as the designated auditor.

08-Nov-2018
(Official Notice)
In terms of the JSE Limited Listings Requirements, a listed company is required to advise shareholders once it receives notice of any change in its external auditors. Argent hereby advises shareholders that the Company?s external auditors, Grant Thornton have joined SizweNtsalubaGobodo, who are now called SNG Grant Thornton, with immediate effect. Mr EY Lakhi will remain as the designated auditor.
30-Oct-2018
(C)
Revenue for the interim period decreased to R19.4 million (2017: R22.5 million), loss for the period narrowed to R2.8 million (2017: loss of R5.7 million), while headline loss per share came to 0.08 cents per share (2017: loss of 0.16 cents per share).



Dividends

No dividends were declared for the six months ended 31 August 2018.



23-Oct-2018
(Official Notice)
Shareholders are referred to the joint firm intention announcement published on SENS on 12 September 2018, wherein shareholders were advised that BMIH would make a mandatory offer to all shareholders of NUT, save for BMIH ("Mandatory Offer"). Shareholders are hereby advised that the joint mandatory offer circular will be posted to NUT shareholders today, 23 October 2018 ("Mandatory Offer Circular").



Accordingly the salient dated and times of the Mandatory Offer are as set out in the table below. The definitions commencing on page 10 of the Mandatory Offer Circular apply to these salient dates and times.

*Record date in order to be eligible to receive this Circular on Friday, 12 October 2018

*Circular posted to Nutritional Shareholders and announced on SENS on Tuesday, 23 October 2018

*Mandatory Offer opens at 09:00 on Wednesday, 24 October 2018

*Last day to trade in order to be eligible to participate in the Mandatory Offer on Tuesday, 4 December 2018

*NUT Shares trade ?ex? the right to participate in the Mandatory Offer - Wednesday, 5 December 2018

*Mandatory Offer closes at 12:00 on (Closing Date) on Friday, 7 December 2018

*Mandatory Offer Record date, being the final date upon which NUT Shareholders must be recorded in the NUT Register in order to be eligible to participate in the Mandatory Offer, on Friday, 7 December 2018

*Mandatory Offer Consideration credited to the Dematerialised Mandatory Offer Participant?s account at his CSDP or Broker (as the case may be) or bank accounts of Certificated Mandatory Offer Participants credited or Mandatory Offer Consideration posted by cheque to Certificated Mandatory Offer Participants at the Certificated Mandatory Offer Participant?s own risk within six Business Days of valid acceptance of the Mandatory Offer with the last payment date being Monday, 10 December 2018

*Results of Mandatory Offer to be published on SENS on Monday, 10 December 2018
11-Oct-2018
(Official Notice)
The Company hereby advises that a reasonable degree of certainty exists that for the 6 month period ended 31 August 2018, loss per share and headline loss per share will be between 0.06 cents and 0.09 cents, representing a decrease of between 40.7% and 60.7% compared to the loss and headline loss per share of 0.16 cents reported for the 6 month period ended 31 August 2017.



The financial information on which this trading statement is based has not been reviewed or reported on by the auditor of the Company. The audited results for the 6 month period ended 31 August 2018 are expected to be published on or about 26th October 2018.
12-Sep-2018
(Official Notice)
10-Sep-2018
(Official Notice)
Shareholders are referred to the announcements released by the Company on SENS on 14 August 2018 and 16 August 2018 advising shareholders that the Company intended to undertake a fully underwritten renounceable rights offer to raise R10 million, before expenses (?Rights Offer?). Baphalane Ba Mantserre Investment Holdings (Pty) Ltd. (?BMIH?) underwrote the Rights Offer.



In terms of the Rights Offer, the Company offered 10 billion ordinary shares (?Rights Offer Shares?) to NUT shareholders at a subscription price of R0.001 per Offer Share, in the ratio of 273.72002 Rights Offer Shares for every 100 ordinary shares held, subject to shareholders being able to apply for no less than ten Rights Offer Shares and in multiples of ten Rights Offer Shares thereafter (?Entitlement?) on the record date of the Rights Offer, being Friday, 24 August 2018.



Results of the rights offer

The Rights Offer closed on Friday, 7 September 2018. Shareholders are advised that a total of 804 517 940 Rights Offer Shares were subscribed for, constituting 8% of the Rights Offer Shares, at a subscription price of R0.001 per Rights Offer Share. The Rights Offer did not included the right for shareholders to apply for excess Rights Offer Shares. Following the finalisation of the Rights Offer, BMIH holds 9 195 482 060 NUT ordinary shares, representing 66.91% of NUT?s issued share capital.



Issue of rights offer shares

Share certificates are being posted to holders of certificated shares who have accepted their Entitlement today, Monday, 10 September 2018. The CSDP or broker accounts of holders of dematerialised shares, who have accepted their Entitlement, will be credited with the Rights Offer Shares and debited with any payments due on Monday, 10 September 2018.



Directors dealings error

Shareholders are referred to the announcement released on SENS on 4 September 2018, wherein it was announced that Mr T Mokgatlha had acquired 1 190 682 080 NUT shares by following his rights through an associate, Philisani (Pty) Ltd. Unfortunately, due to administrative errors, this share acquisition was not timeously concluded.
05-Sep-2018
(Official Notice)
The board of directors of the Company advised that Mr G Wamback and Dr C Kapnias have resigned as non-executive directors of the Company with effect from 31 August 2018.



Appointment of directors

In addition, the Board advise that Dr PJ Mokgothu and Ms PM Chabeli have been appointed as independent non-executive directors of the Company with effect from 31 August 2018.
31-Aug-2018
(Official Notice)
Shareholders are hereby advised that the results of the voting of the annual general meeting of the Company held on Friday, 31 August 2018 at Unit 20 at The Boulevard Business Park, 14 Belladonna Road, Cornubia Industrial Park (?AGM?).
16-Aug-2018
(Official Notice)
14-Aug-2018
(Official Notice)
08-Aug-2018
(Official Notice)
The board of NUT wishes to advise all shareholders that the Company has transferred responsibility of Transfer Secretarial services to 4 Africa Exchange Registry (Pty) Ltd., with immediate effect.

The new contact details are as follows:

4 Africa Exchange Registry (Pty) Ltd.

Cedarwood House

Ballywoods Office Park

33 Ballyclare Drive

Bryanston

2191

South Africa
10-Jul-2018
(Official Notice)
Shareholders of the company (?shareholders?) are hereby referred to the announcement released on SENS on 29 June 2018 wherein the company advised that the company?s integrated annual report (?Integrated Report?), incorporating the full audited consolidated annual financial statements of the company for the year ended 28 February 2018 (?Annual Financial Statements?) and the notice of the annual general meeting of the company (?AGM?) contained no modifications to the results which were announced on SENS on 30 May 2018 (?SENS Announcement?).



Shareholders are hereby advised of the following modifications between the Annual Financial Statements and the SENS Announcement:

On the Statement of Financial Position the Deferred tax asset and Deferred tax liability were different due to an allocation error between the Asset and Liability:

SENS Announcement, Integrated Report and Difference R'000

Deferred tax asset : 5 568; 5 424; 144

Deferred tax liability : (5 568); (5 424); (144)

Net deferred tax balance : -; -; -



On the Statement of Cash flows the disclosure on the disposal of the subsidiary needed to be amended in the Integrated Report. The difference in disclosure is as follows:

SENS Announcement, Integrated Report and Difference R'000

Disposal of Subsidiary : 2 771; 287; 2 484

Cash flow from operating activities : (5 905); (3 421); (2 484)

Combined cash flow effect : (3 134); (3 134); -
03-Jul-2018
(Official Notice)
Shareholders are referred to the SENS announcement released on 29 May 2018 wherein the Company announced that it had finalized negotiations with Baphalane Ba Mantserre Investment Holding (Pty) Ltd. (?BBMIH?) to underwrite a R10 000 000 Claw Back Rights Issue at R0.001 per share (?the Issue?).



Consequently, the Company has been advised that Mr. Thabo Mokgatlha has resigned as chief executive officer of the Company with immediate effect. Mr. Mokgatlha will remain involved with the Company and has been appointed as a non-executive director, and a representative of BBMIH on the board of NUT with immediate effect. The board wishes to thank Thabo for his years of service and looks forward to his continued input as a non- executive director moving forward.



Mr. Rob Etchells has been appointed as chief executive officer of the Company with immediate effect, having previously served at the chief operating officer. Mr Etchells will also continue in his role as the financial director of the Company for an interim, during which period the board will look to permanently appoint a suitable candidate as the financial director of the Company.
29-Jun-2018
(Official Notice)
Shareholders of the company (?shareholders?) are hereby advised that the company?s integrated annual report (?Integrated Report?), incorporating the full audited consolidated annual financial statements of the company for the year ended 28 February 2018 (?Annual Financial Statements?) and the notice of the annual general meeting of the company (?AGM?) was dispatched to Shareholders today, 29 June 2018, and contains no modifications to the results which were announced on SENS on 30 May 2018.



The Integrated Report and the Annual Financial Statements will also be available on the company?s website, www.nholdings.co.za at as from today, 29 June 2018.



Notice of AGM

Notice is hereby given that the AGM will be held at 10h00 on Friday, 31 August 2018 at Unit 20, The Boulevard Business Park, 14 Belladonna Road, Cornubia Industrial Park, Durban to transact the business as set out in the notice of AGM which forms part of the Integrated Report.



The date on which Shareholders must be recorded as such in the share register of the company to be eligible to vote at the AGM is Friday, 24 August 2018 with the last day to trade being Tuesday, 21 August 2018.
30-May-2018
(C)
Revenue for the year lowered to R42.5 million (2017: R43.2 million). Operating loss before interest and taxation narrowed to R9.7 million (2017: loss of R14.9 million). Loss for the year lowered to R13.8 million (2017: loss of R17 million). Furthermore, headline loss per share was 0.31 cents per share (2017: loss of 0.24 cents per share).



Dividend

No dividend has been declared for the year.
29-May-2018
(Official Notice)
Shareholders are referred to the various SENS announcements released during the past 6 months where-in the Board of Directors (?Board?) have informed shareholders of the stressed cash flow and poor trading conditions which have resulted in the Company continuing to incur losses at both its operating units and service division.



During the past six months, the Board has engaged with various parties with the aim of securing off-take agreements for the Nutritional Foods factory as well as the necessary working capital to be able to fund the increase in tonnages pushed through the factory. The Board is please to advise shareholders that it has finalized negotiations with Baphalane Ba Mantserre Investment Holding (Pty) Ltd to underwrite a R10 000 000 Claw Back Rights Issue at R0.001 per share (?the Issue?), of which there are no outstanding conditions precedent. Shareholders will be advised of the full details of the Issue in due course.

17-May-2018
(Official Notice)
Further to the trading statement released on SENS on 10 May 2018, and after consultation with the Company?s auditors, shareholders are advised that for the year ended 28 February 2018, the loss per share is expected to be between 11.97% and 31.97% lower, not higher as previously announced, than the loss reported for the year ending 28 February 2017 (?Comparative Period?) of 0.49 cents per share, at between 0.33 and 0.43 cents per share. Headline loss per share is expected to be between 18.47% and 38.47% higher than the loss reported for the Comparative Period of 0.24 cents per share, at between 0.29 and 0.34 cents per share.



The information in this trading statement has neither been reviewed nor reported on by the Company?s external auditors.



The results for the year ended 28 February 2018 are expected to be released on SENS on or about 31 May 2018.
10-May-2018
(Official Notice)
Shareholders are hereby advised that the basic loss per share and headline loss per share attributable to ordinary shareholders for the year ended 28 February 2018 are expected to increase by more than 20%, as compared to those reported for the previous corresponding period.



A more detailed trading statement will be published in due course.
04-Apr-2018
(Official Notice)
Shareholders are referred to the SENs announcements released on 30 September 2016 and 7 November 2016.



Shareholders are hereby advised that NUT and Ontario Private Equity P(Pty) Ltd. (?Ontario?), the parties to the Acquisition Agreement (?Agreement?) have agreed that the achievement by VSS of the ?profit warranty? contained in the Agreement is highly unlikely and as such NUT and Ontario have agreed by mutual consent to cancel the Agreement.



The cancellation will place both parties back into the same financial position they were prior to signing the Agreement.



Based on the cancellation of the Agreement the Company will continue to focus on its core food manufacturing business and has abandoned the proposed shift in focus to the renewable energy sector.
23-Jan-2018
(Official Notice)
In terms of paragraph 3.91 of the JSE Listings Requirements, the board of directors (?Board?) advise that all the resolutions, as set out in the notice of the GM, were passed by a majority of shareholder votes at the GM held today at 5 Sneezewood Lane, Glen Anil, Durban. Altogether 47% of voteable shares, being 1 761 249 315 shares, were represented at the AGM.

22-Dec-2017
(Official Notice)
Shareholders are referred to the various announcements by NUT published on SENS relating to the continued losses incurred by the Company and the requirement by the Company to seek additional funding. Further to the above, Nutritional Foods has recently seen an influx of new customers providing much needed throughput at the factory. This has presented management with a need to secure additional working capital to be able to service these new orders. Accordingly, the board of the Company needs to seek alternative sources of funding, which funding may include a fresh issue of shares for cash or any other form of fund raising that will increase the cash available to the Company, including a potential rights offer (?Capital Raise?).



Accordingly, the Company intends to increase its authorised share capital. To this extent the Company is proposing amendments to its memorandum of incorporation (?MOI?).



In addition, in anticipation of the additional shares that may be issued in terms of the Capital Raise, the Company is proposing the approval of a resolution in terms of section 41(3) of the Companies Act No. 71 of 2008, as amended (?the Act?).



Shareholders are hereby advised that the circular was distributed to shareholders on Friday, 22 December 2017.



Notice of general meeting

Notice is hereby given that a general meeting of NUT shareholders will be held at 10:00 on Tuesday, 23 January 2018, at the Boardroom of Great Wall Motors SA (Pty) Ltd, 5 Sneezewood Lane, Glen Anil, Durban (?the General Meeting?), to consider and if deemed fit approve, the resolutions relating to the amendments to the Company?s MOI and the resolution in terms of section 41(3) of the Act as contained in the notice of General Meeting which forms part of the circular.



The date on which shareholders must be recorded in the share register of the Company for purposes of being entitled to attend and vote at the General Meeting is Friday, 12 January 2018, with the last day to trade being Tuesday, 9 January 2018. The Circular incorporating the notice of general meeting is also available on the Company?s website www.nholdings.co.za and can be viewed at its offices at Unit 20, The Boulevard Business Park, 14 Belladonna Road, Cornubia, 4319, during office hours.

20-Oct-2017
(C)
Revenue for the interim period increased to R22.5 million (2016: R21.8 million), loss for the period soared to R5.7 million (2016: loss of R2.3 million), while headline loss per share worsened to 0.16 cents per share (2016: loss of 0.07 cents per share).



Dividends

No dividends were declared for the six months ended 31 August 2017.



Going concern

As stated in the commentary above the Company has continued to make operating losses. These losses have placed further negative stress on the Company?s cash flow situation and as such raised certain issues regarding the going concern assumption. Management has been forced to review the current status of the Company?s disposable cash resources as well as its commitments to repay its overdraft facilities and certain shareholders loans. The Company?s bankers continue to support the operations of its major subsidiary, being Nutritional Foods, but are reducing NUT?s ? the holding company?s - facilities on a monthly basis. Management has been able to accommodate the reduction in NUT?s overdraft facilities via own funding but the need to repay the shareholders and unsecured loans of R10.797 million at the end of March 2018 is of concern. Management is of the opinion that the substantial doubt surrounding its ability to fund its monthly operations as well as the re-negotiation of the shareholders loans due on the 31st of March 2018 place the going concern assumption in doubt.



Accordingly shareholders are advised that management are perusing all avenues including the sale of its major asset, Nutritional Foods, to raise capital in order to meeting the company?s financial obligations as and when they fall due. The outcome of these discussions, whilst ongoing, are unknown at this point in time.



Shareholders are advised that the unaudited condensed consolidated interim results for the six months ended 31 August 2017 have been prepared on the going concern concept and do not reflect any effects of the substantial uncertainties over the going concern assumption. This basis presumes that funds will be available to finance future operations and that the realization of assets and settlement of liabilities, contingent obligations and commitments will occur in the ordinary course of business.
15-Sep-2017
(Official Notice)
Shareholders are hereby advised that the basic earnings per share and headline earnings per share attributable to ordinary shareholders for the six months ended 31 August 2017 are expected to differ by more than 20%, as compared to those reported for the previous corresponding period.



The board of directors (?the board?) of the company considers it pertinent to bring to the attention of shareholders that the company has continued to generate losses in the current period which has had a further negative impact on the cash resources available to the company.



Accordingly, shareholders are advised that the board is busy with discussions relating to all options available to re-capitalize the company and will revert to Shareholders in due course, once progress made.



Shareholders are referred to the SENS announcements released on the 30 August 2016 and 7 November 2016, wherein Shareholders were advised of the board?s decision to diversify the company?s exposure to include investments outside the food manufacturing sector to that of industrial, manufacturing and renewable energy, which to date have not been successful.



It should be noted that the executive directors have agreed to forgo their monthly salaries for a further period of 3 months in an effort to reduce the monthly cash flow pressure of the company whilst the board pursues the re-capitalisation of the company as well as the finalization of it?s discussions on the possible reversal of the proposed renewable energy assets into the company.
01-Sep-2017
(Official Notice)
The board of directors advised that all the resolutions, including the special resolutions, as set out in the notice of the AGM, were passed by a comprehensive majority of shareholder votes at the AGM held today, 1 September 2017, at 5 Sneezewood Lane, Glen Anil, Durban.
31-May-2017
(C)
Revenue for the year increased to R43.2 million (2016: R38.3 million). Operating loss before interest, and taxation was recorded at R14.9 million (2016: loss of R4.7 million), loss for the year came in at R17 million (2016: loss of R5.4 million), while headline loss per share was at 0.24cps (2016: loss of 0.16cps).



Dividend

No dividend has been declared for the year.



Notice of annual general meeting

Shareholders are hereby advised that the integrated annual report was released today, which incorporates the notice of annual general meeting to be held at the Boardroom of Great Wall Motors SA (Pty) Ltd, 5 Sneezewood Lane, Glen Anil, Durban on Friday, 1 September 2017 at 10h00. The integrated report will also be available on the company?s website at www.nholdings.co.za.



The date on which shareholders must be recorded as such in the share register for purposes of being entitled to attend and vote at this meeting is Friday, 25 August 2017 with the last day to trade being Tuesday, 22 August 2017.

11-May-2017
(Official Notice)
Further to the trading statement released on SENS on 24 April 2017, shareholders are advised that for the year ended 28 February 2017, loss per share is expected to be between 196.43% and 216.43% more than that for the year ended 29 February 2016 (?comparative period?) at between 0.471 and 0.503 cents per share and headline loss per share is expected to be between 42.57% and 62.57% more than that for the comparative period at between 0.227 and 0.259 cents (comparative period loss per share and headline loss per share of 0.159 cents per share).



During the period under review trading conditions remained extremely challenging with LSM 3-6 customers bearing the brunt of the high maize price as well as other bulk raw materials used in the manufacture of staple dry food products. This has had a detrimental effect on the trading margins achieved at Nutritional Foods. In addition the disposal of the registered dossiers owned by Impilo Drugs in September 2016 triggered a write down of the intangible assets in the company of R11.7 million



The financial information on which this trading statement is based has not been reviewed and reported on by the company?s external auditors.



The results for the year ended 28 February 2017 are expected to be released on SENS on or about 31 May 2017.

24-Apr-2017
(Official Notice)
Shareholders are hereby advised that the basic loss per share and headline loss per share attributable to ordinary shareholders for the year ended 28 February 2017 are expected to increase by more than 20%, as compared to those reported for the previous corresponding period.



During the period under review trading conditions in the staple dry food environment remain extremely challenging with LSM 3-6 customers bearing the brunt of the high maize price as well as other bulk raw materials used in the manufacture of these products.



Furthermore the disposal of the registered dossiers owned by Impilo Drugs in September 2016 triggered a write down of the intangible assets in the company of R11.7 million.



A more detailed trading statement will be published in due course.
07-Nov-2016
(Official Notice)
03-Nov-2016
(C)
Revenue for the interim period increased to R21.8 million (R18.2 million). Gross profit also increased to R8.4 million (R6.5 million). Operating loss before interest narrowed to R1.6 million (loss of R2.1 million). Loss for the period remained constant at R2.3 million (loss of R2.3 million). In addition, headline loss per share improved slightly to 0.07cps (headline loss per share of 0.08cps).



Dividends

No dividends were declared for the six months ended 31 August 2016.
30-Sep-2016
(Official Notice)
The board of directors (?Board?) advise that all the resolutions, including the special resolutions, as set out in the notice of the AGM, were passed by a comprehensive majority of shareholder votes at the AGM held today at the registered offices of the company.



Altogether 62.77% of voteable shares, being 3 497 368 179 shares, were represented at the AGM.







30-Sep-2016
(Official Notice)
Shareholders are advised that the company has issued 200 000 000 ordinary NUT shares to Ontario Private Equity (Pty) Ltd. (?Ontario?) at an issue price of 2 cents per share for a total consideration of R4 million (?the Subscription?), being a premium of 75% to the 30 day VWAP calculated on 16 September 2016, being the date prior to the date that the parties entered into the Subscription agreement.



The Subscription is in terms of a general authority to issue shares for cash which approval was granted by NUT shareholders at the company?s annual general meeting on 3 July 2015, and constitutes 5.72% of the number of equity securities in issue prior to the Subscription.



The proceeds of the Subscription will be used to partially repay debt and the balance to provide working capital to the company and its operating subsidiaries.



Renewal of cautionary announcement

Shareholders are referred to the cautionary announcement released on SENS on 30 August 2016 and are advised that the company is still in discussions with Ontario with a view to reverse listing certain companies within Ontario?s portfolio into NUT.



These discussions if successfully concluded may have a material effect on the price of the company?s securities.



Accordingly, shareholders are advised to continue to exercise caution when dealing in the company?s securities until a further announcement is made.



26-Sep-2016
(Official Notice)
30-Aug-2016
(Official Notice)
Shareholders are advised that the company has engaged with Ontario Private Equity (Pty) Ltd. (?Ontario?) with a view to reverse listing certain companies within Ontario?S portfolio into NUT. Management have undertaken to commence with due diligence investigations and will report back to shareholders in due course.



These discussions if successfully concluded may have a material effect on the price of the company?s securities.



Accordingly, shareholders are advised to exercise caution when dealing in the company?s securities until a further announcement is made.

16-Aug-2016
(Official Notice)
Shareholders are hereby advised that Nutritional?s annual report, containing the audited group financial statements for the year ended 29 February 2016, was distributed to shareholders today, and contains no modifications to the audited results which were announced on SENS on 24 May 2016. The annual report is also available at www.nholdings.co.za.



Notice of annual general meeting

Notice is hereby given that the annual general meeting of Nutritional will be held at 5 Sneezewood Lane, Glen Anil, Durban, on Friday, 30 September 2016 at 10h00 to transact the business as set out in the notice of the annual general meeting on pages 70 to 76 of the annual report.



The date on which shareholders must be recorded as such in the share register to be eligible to vote at the annual general meeting is Friday, 23 September 2016, with the last day to trade being Tuesday, 20 September 2016.
08-Aug-2016
(Official Notice)
Shareholders are referred to SENS announcement released on the 25th April 2016 pertaining to the acquisition of Kairos Nutrition (Pty) Ltd (KAIROS) (?the Acquisition?). The Acquisition was subject to certain suspensive conditions.



Shareholders are hereby advised that, due to the uncertainty of achieving targets set as part of the suspensive conditions, management of both KAIROS and NUT have mutually agreed not to proceed with the acquisition.



Resignation of director

In terms of the acquisition Mr Ian Murgatroyd was appointed as director of the company effective 25 April 2016. In terms of management?s decision not to proceed with the acquisition Mr Murgatroyd has resigned as a director of the company effective 8 August 2016.



Mr Murgatroyd will continue to serve as a consultant to the company as part of its target of penetrating the main stream FMCG market space.



02-Jun-2016
(Official Notice)
Shareholders are referred to the SENS announcement of 24 May 2016 regarding the audited year results for the period ended 29 February 2016. Shareholders are advised that Grant Thornton have issued an unmodified audit report on the annual financial statements for the year ended 29 February 2016 and their unmodified audit report is available for inspection at the Company?s registered office.
24-May-2016
(C)
Revenue for the year increased to R38.3 million (2015: R37.8 million). Operating loss before interest, taxation and impairment widened to R4.7 million (2015: loss of R4.1 million), loss for the year came in at R5.4 million (2015: loss of R3.2 million), while headline loss per share was at 0.16cps (2015: loss of 0.15cps).



Dividend

No dividend has been declared for the year.



25-Apr-2016
(Official Notice)
Shareholders are hereby advised that the Company has entered into an agreement to acquire the entire shareholding of Kairos on 25 April 2016 (?the Acquisition?). The effective date of the Acquisition will be 1 May 2016.



Kairos has recently been awarded certain contracts for the supply of infant feed to combat malnutrition and will compliment the Company?s strategy with regards the supply of essential staple foods. The purchase consideration is payable via the issue of a maximum of 70 million NUT shares at an issue price of 2 cents per share (?Purchase Consideration?). The Purchase Consideration is to be settled in two equal tranches, the first being upon fulfilment of the suspensive conditions being fulfilled within 21 days of signature of the Acquisition agreement, and the second on attainment of the profit warranty stipulated in the Acquisition agreement.



Kairos will continue to be headed up by Mrs Michelle Bristow. Michelle holds a BSc.Dietetics (Hons) from Stellenbosch University. Michelle is a registered dietician and has worked for various pharmaceutical companies both in South Africa and the United Kingdom over the past 15 years. Her extensive knowledge will assist the Group in attaining it?s desired goal of becoming a primary provider of nutritional staple foods products throughout Southern Africa.



Appointment of director

Shareholders are further advised of the appointment of Mr Ian Murgatroyd as Commercial Director of NUT with effect from 25 April 2016.
23-Mar-2016
(Official Notice)
Shareholders are advised that Nutritional will change its transfer secretarial function to Trifecta Capital Services (Pty) Ltd, with effect from 4 April 2016.



The new Transfer Secretary?s contact details, for existing and prospective shareholders, are:

Trifecta Capital Services (Pty) Ltd

Trifecta Capital House

31 Beacon Road

Florida-North

1709

South Africa



T: +27 (0) 860 22 22 13

E: nutritional@trifectacapital.com

Postal Address:

PO Box 61272

Marshalltown

2107

South Africa
15-Feb-2016
(Official Notice)
Shareholders are advised of the resignation of Mr T Hendry as an independent non- executive director with effect from 12 February 2016.
15-Jan-2016
(Official Notice)
Shareholders are referred to the terms announcement published by the Company dated 16 November 2015 relating to a subscription of 1 500 000 000 shares for R39 500 000 in cash with the Imisebeyelanga Nazareth Baptist Church Trust (?Subscriber?) (?the Subscription?) by way of a general issue of shares for cash. Shareholders are hereby advised that all the conditions precedent to the Subscription were fulfilled, other than the funds being transferred into the Company?s bank account and approval of the issue of NUT shares by the JSE Ltd., prior to 31 December 2015.



The board has been actively engaging with the Subscriber regarding the transfer of funds and despite having placed the Subscriber in breach, in terms of the Subscription Agreement, payment has not been forthcoming. The breach period has expired today leaving the board with no other option but to cancel the Subscription Agreement. Shareholders will be updated of progress made in the Company?s fund raising efforts in due course.
23-Nov-2015
(Official Notice)
Shareholders are referred to the terms announcement published by the company dated 16 November 2015 relating to a subscription of 1 500 000 000 shares for R39 500 000 in cash with the Imisebeyelanga Nazareth Baptist Church Trust (?Subscriber?) (?the Subscription?).



The Subscription is categorised as a general issue of shares for cash in terms of the Listings Requirements of the JSE and in terms of the resolution approved by shareholders at the NUT AGM held on 3 July 2015.



Posting of circular relating to section 41(3) shareholder approval

In terms section 41(3) of the Companies Act, No. 71 of 2008, as amended (?the Companies Act?), an issue of shares in a transaction, or a series of integrated transactions, requires approval of the shareholders by special resolution if the voting power of the class of shares that are issued or issuable as a result of the transaction or series of integrated transactions will be equal to or exceed 30% of the voting power of all the shares of that class held by shareholders immediately before the transaction or series of transactions.



As more than 30% of the company?s issued share capital will be issued to the Subscriber, the approval of NUT shareholders by way of a special resolution is required.



The board of directors of the company has, accordingly, proposed a special resolution, to be circulated and voted on in writing, in terms of section 60 of the Companies Act, in order to obtain the requisite shareholder approval necessary to enable it to successfully implement the Subscription (?Section 41(3) Circular?).



The Section 41(3) Circular was posted to shareholders today, Monday, 23 November 2015.



The Section 41(3) Circular is also available on the company?s website www.nholdings.co.za and can be viewed at its offices at 49 Richefond Circle, Ridgeside Office Estate, Umhlanga Rocks, 4319, during office hours.
16-Nov-2015
(Official Notice)
16-Nov-2015
(C)
Revenue for the interim period lowered to R18.2 million (R19.3 million). Gross profit also decreased to R6.5 million (R7.8 million). Operating loss before interest widened to R2.1 million (loss of R1.6 million). Loss attributable to ordinary shareholders worsened to R2.3 million (loss of R2.0 million). In addition, headline loss per share improved slightly to 0.08cps (0.11cps).



Dividends

No dividends were declared as at 31 August 2015.
23-Oct-2015
(Official Notice)
Shareholders are hereby advised that the Company is expecting basic loss per share and headline loss per share attributable to ordinary shareholders for the interim period ended 31 August 2015 to improve by 25%, being a loss per share of 7.93 cents per share as compared to those reported for the previous corresponding period being a loss and headline loss of 10.62 cents per share.



However, the Company is expecting it?s basic loss attributable to ordinary shareholders for the interim period ended 31 August 2015 to have increased negatively at less than 20% than that for the interim period ended 31 August 2014. The financial results for the interim period ended 31 August 2015 are expected to be released on or about 15 November 2015.
31-Aug-2015
(Official Notice)
Shareholders are referred to the disclosure of the summons served on the company on 30 October 2009 by the Tully Family Trust (?Tully?) as detailed on page 26 of the company?s 2014 Annual Integrated Report.



The Board is pleased to advise shareholders that the company and Tully have resolved the dispute and that all pending legal actions against the company have been withdrawn by Tully.
03-Jul-2015
(Official Notice)
In terms of paragraph 3.91 of the JSE Listings Requirements, the Board of directors advise that all the resolutions, including the four special resolutions, as set out in the notice of the AGM, were passed by a comprehensive majority of shareholder votes at the AGM held on 3 July 2015 at the registered offices of the Company.



Altogether 54.22% of voteable shares, being 1 896 223 583 shares, were represented at the AGM.



None of the special resolutions adopted requires registration with the Companies and Intellectual Property Commission.
29-May-2015
(C)
Revenue for the year increased to R37.8 million (2014: R36.3 million). Operating loss before interest, taxation and impairment narrowed to R4.1 million (2014: loss of R5.6 million), loss for the year lowered to R3.2 million (2014: loss of R6.2 million), while headline loss per share improved to 0.15cps (2014: loss of 0.32cps).



Dividend

No dividend has been declared for the year.



Notice of AGM

Shareholders were advised that the integrated annual report was released on 29 May 2015, which incorporates the notice of annual general meeting to be held at 5 Sneezewood Lane, Glen Anil, Durban on Friday, 3 July 2015 at 10h00. The integrated report will also be available on the company?s website at www.nholdings.co.za. The date on which shareholders must be recorded as such in the share register for purposes of being entitled to attend and vote at this meeting is Friday, 26 June 2015 with the last day to trade being Friday, 19 June 2015.
29-Apr-2015
(Official Notice)
Shareholders are advised that further to the trading statement released on 21 April 2015, the Company is expecting it?s basic loss per share attributable to ordinary shareholders for the year ended 28 February 2015 to improve by between 44% and 64% being a loss per share of between 12 and 18 cents per share as compared to those reported for the previous corresponding period being a loss of 32 cents per share.



The headline loss per share attributable to ordinary shareholders for the year ended 28 February 2015 is expected to improve by between 42% and 62% being a loss per share of between 12 and 18 cents per share compared to headline loss per share for the previous corresponding period, being a loss of 32 cents per share.



The financial results for the year ended 28 February 2015 are expected to be released on or about 22 May 2015.
21-Apr-2015
(Official Notice)
Shareholders are hereby advised that the basic earnings per share and headline earnings per share attributable to ordinary shareholders for the year ended 28 February 2015 are expected to improve by more than 20% compared to that reported for the previous corresponding period.



At this stage, the Company is unable to quantify, with a reasonable degree of certainty, the specific number, percentage or range to describe the difference and an updated trading statement will therefore be released once the Company is able to quantify the expected number, percentage or range of the improvement in the financial results.
09-Feb-2015
(Official Notice)
30-Jan-2015
(Official Notice)
Shareholders are advised that Mr Clayton Angus, the Company?s Financial Director has resigned from the Company with effect from 2 March 2015. Mr Rob Etchells has been appointed as Financial Director effective 3 March 2015. In addition to fulfilling the role of Financial Director, Mr Etchells will continue to serve as the Chief Operating Officer of the company.
19-Dec-2014
(Official Notice)
Shareholders are referred to the circular dated 4 November 2014 relating to a specific issue of shares for cash to a black economic empowerment (?BEE?) consortium.



Shareholders are hereby advised that special resolution 1 relating to the increase in the Company?s authorised share capital has been lodged and registered by the CIPC and that 1 000 000 000 ordinary NUT shares will be issued at a price of R0.01 per share to the BEE consortium on 19 December 2014.

08-Dec-2014
(Official Notice)
Further to the announcement released on 5 December 2014 wherein shareholders were advised that all resolutions pertaining to the proposed BEE transaction were passed, shareholders are advised that Mr Thabo Mokgatlha CA(SA) has been appointed as the Chief Executive Director of the Company effective 1 January 2015.



Mr Rob Etchells will remain as a director of the Company as Chief Operating Officer.



The board wishes to thank Rob for his dedication and steadfast commitment to the turnaround process undertaken during the past 18 months and looks forward to his continued contribution in the next phase of the Company?s strategy to unlock shareholder?s wealth.

05-Dec-2014
(Official Notice)
In terms of paragraph 3.91 of the JSE Listings Requirements, the Board of Directors advise that all the resolutions, including the two special resolutions, as set out in the notice of the GM, were passed by shareholders at the GM held today at the registered offices of the Company. Altogether 54.99% of voteable shares, being 1 098 325 771 ordinary shares, were represented at the GM, however, in respect of ordinary resolution number 1, the 90 000 000 treasury shares were not voted nor counted into voteable shares. Furthermore, in respect of ordinary resolution number 1, 588 305 173 shares were not eligible to vote in terms of the JSE Listings Requirements.



06-Nov-2014
(C)
Revenue for the interim period increased to R19.3 million (R19.2 million), while gross profit decreased to R7.8 million (R8.0 million). Operating loss before interest was to R1.6 million (loss of R1.7 million). Comprehensive loss attributable to ordinary shareholders decreased to R2.0 million (loss of R1.9 million). Headline loss per share fell to 0.11cps (loss of 0.10cps).



Prospects

The BEE transaction will see Philiani inject much needed funding into the Group as well as create a base from which management will be able to unlock the potential of its dry food manufacturing plant in Klerksdorp. Upon the successful conclusion of the BEE transaction Mr Mokgatahla will take up the position of Group Chief Executive Officer. Mr Rob Etchells will remain a director of the Company as the Chief Operating Officer.

04-Nov-2014
(Official Notice)
Shareholders are referred to the terms announcement published by the Company dated 14 October 2014 relating to a specific issue of shares for cash to a black economic empowerment ("BEE") consortium ("the BEE Subscription"). Shareholders were advised that the JSE has formally approved the circular relating to the BEE Subscription ("the Circular") and that the Circular was distributed to shareholders on 4 November 2014.



Notice of GM

Notice was given that a general meeting of NUT shareholders will be held at 14:00 on Friday, 5 December 2014, at the Boardroom of Great Wall Motors SA (Pty) Ltd., 5 Sneezewood Lane, Glen Anil, Durban ("the General Meeting"), to consider and if deemed fit approve, the resolutions relating to the BEE Subscription as contained in the notice of General Meeting which forms part of the Circular.



The date on which shareholders must be recorded in the share register of the Company for purposes of being entitled to attend and vote at the General Meeting is Friday, 28 November 2014, with the last day to trade being Friday, 21 November 2014. The Circular incorporating the notice of General Meeting is also available on the Company's website www.nholdings.co.za and can be viewed at its offices at 49 Richefond Circle, Ridgeside Office Estate, Umhlanga Rocks, 4319, during office hours.
14-Oct-2014
(Official Notice)
29-Aug-2014
(Official Notice)
Shareholders are advised that, at the annual general meeting of shareholders of Nutritional Holdings held today, 29 August 2014, at 10h00 at 5 Sneezewood Lane, Glen Anil, Durban, all of the proposed ordinary and special resolutions, as contained in the notice of annual general meeting, were passed by the requisite majority of shareholders present and voting in person or by proxy.

15-Aug-2014
(Official Notice)
In line with the policy of the board of directors ("the board") to maintain high-quality corporate governance and in compliance with paragraph 3.59(b) of the Listings Requirements of the JSE Ltd. and to ensure compliance with King III, shareholders are hereby informed of the following changes to the board and members of board committees:



*the resignation of Mrs JA Etchells as a non-executive director from the board. Mrs Etchells will remain as Company Secretary;

*the resignation of Mr AR Pinfold as a member of the audit committee;

*the appointment of Mr AR Pinfold as a member of the remuneration committee;

*the appointment of Dr C Kapnias as an independent non-executive director to the board as well as a member of the audit committee.



Dr Kapnias operated in private practice from 1993 to 2006. He then moved his attention to the Wellness and Nutriceutical industry, having owned various companies in the preventative medicine market. He has been integrally involved in sports performance and sports injury rehabilitation and has worked with various international athletes and sports teams over the years.



Dr Kapnias has been involved in HIV research for a number of years having collaborated with Prof Richard Bunn from the Medical Research Council of South Africa and brings with him a unique skill-set that will enhance the Company?s ability to unlock potential in those markets segments that Nutritional has traditionally operated in as well as new markets where the Company?s product base has synergy.



The abovementioned changes will all be effective from 15 August 2014.



13-Aug-2014
(Official Notice)
12-Jun-2014
(Official Notice)
Further to the publication of the results announcement on SENS on Friday, 30 May 2014, regarding the company's audited group results for the year ended 28 February 2014, shareholders are advised that the company's 2014 Integrated Report, which incorporates the audited annual financial statements for the period, is available on its website at www.nholdings.co.za or can be obtained from the company's registered office, from today, 12 June 2014, and contains no modifications from the aforementioned SENS announcement.



Notice of annual general meeting

The notice of annual general meeting, containing the abridged annual financial statements will be distributed to shareholders on or about 18 June 2014 and accordingly notice is hereby given that the annual general meeting of Nutritional will be held at Great Wall Motors SA (Pty) Ltd, 5 Sneezewood Lane, Glen Anil, Durban on Friday, 29 August 2014, at 10:00, to transact the business as set out in the notice of annual general meeting.



The date on which shareholders must be recorded in the share register for purposes of being entitled to attend and vote at the annual general meeting is Friday, 22 August 2014, with the last day to trade being Friday, 15 August 2014.
05-Jun-2014
(Official Notice)
The Johannesburg Stock Exchange ("JSE") advised that the auditor's report on the company's Audited Provisional financial results for the year ended 28 February 2014 contains a modification. Shareholders are advised to refer to the results which were recently published on SENS to ascertain the exact nature of the modification. Accordingly, the company's listing on the trading system will be annotated with an "E" to indicate the modification. The annotation will be removed when the company's auditor's report no longer contains a modification.
30-May-2014
(C)
Revenue for the year rose to R36.0 million (R34.2 million) and operating loss before interest, taxation and impairment narrowed to R5.6 million (loss of R5.9 million). Loss attributable to ordinary shareholders lowered to R6.2 million (loss of R13.4 million). Furthermore, headline loss per share came down to 0.32cps (loss of 0.41cps).



Dividend

In view of the Group's current financial position, no dividend has been declared for the year.



Prospects

During the year under review management's strategy of transforming the Group's activities into three legs, being the manufacture and sale of traditional products into industrial kitchens/feeding schemes, entry into the FMCG market and 3rd party contract/toll manufacturing has taken longer than originally expected due to very tight cash flow constraints and price competitive issues due to efficiencies at the Klerksdorp factory. Management are however confident that with increased volumes it will be able to improve overhead recoveries which in turn will assist with its ability to become more competitive from a pricing perspective. In this regard management have been actively discussing possible joint ventures and co-branding opportunities with strategic partners. This strategy will continue during the coming financial year with the intention of unlocking production potential at the Klerksdorp manufacturing plant. With the move of all manufacturing of its pharmaceutical division to a new 3rd party contract manufacturer, management expect gross margins to increase as well as to become more competitive in the market place regarding pricing on the shelf. Management have identified the need to introduce a Broad Based Black Economic Empowerment partner to facilitate growth in the industrial catering environment within the mining industry, as well as access to government tenders in state run facilities, and are actively pursuing this at present.
22-May-2014
(Official Notice)
Shareholders are informed that Mr Anthony Spanjaard ("Anthony") has resigned as director from the board of directors of Nutrition) with effect from 21 May 2014.
13-May-2014
(Official Notice)
Shareholders are advised that further to the trading statement released on 25 April 2014, the Company is expecting it's basic loss per share attributable to ordinary shareholders for the year ended 28 February 2014 to improve by between 54% and 74% as compared to those reported for the previous corresponding period and the headline loss per share attributable to ordinary shareholders for the year ended 28 February 2014 to improve by between 13% and 33% compared to headline loss per share for the previous corresponding period. The financial results for the year ended 28 February 2014 are expected to be released on or about 28 May 2014.
25-Apr-2014
(Official Notice)
Shareholders are hereby advised that the basic earnings per share and headline earnings per share attributable to ordinary shareholders for the year ended 31 March 2014 are expected to improve by more than 20% compared to that reported for the previous corresponding period.



At this stage, the company is unable to quantify, with a reasonable degree of certainty, the specific number, percentage or range to describe the difference and an updated trading statement will therefore be released once the company is able to quantify the expected number, percentage or range of the improvement in the financial results. The information contained in this trading statement has neither been reviewed nor reported on by the company's external auditors.

24-Oct-2013
(C)
Revenue for the interim period increased to R19.2 million (R17.5 million) and gross profit rose to R8.0 million (R7.0 million). Operating loss before interest narrowed to R1.7 million (loss of R3.7 million). Comprehensive loss attributable to ordinary shareholders decreased to R1.9 million (loss of R3.7 million). Headline loss per share fell to 0.1cps (loss of 0.26cps).
15-Oct-2013
(Official Notice)
Shareholders were advised that further to the trading statement released on SENS on Tuesday, 7 October 2013, the company is expecting it's basic loss per share for the six months ended 31 August 2013 to improve by between 57% and 67% compared to the loss per share for the previous corresponding period and the headline loss per share for the six months ended 31 August 2013 to improve by between 57% and 67% compared to headline loss per share for the previous corresponding period.



Improvements in the company's operating loss were largely as a result of the operational efficiency and business improvement initiatives presented at the year-end announcement made in May 2013. These initiatives remain priority and are expected to continue to bear fruit in the future. The company's gearing remains low at 13.7%, calculated as at 31 August 2013. The financial results for the six months ended 31 August 2013 are expected to be released on or about 21 October 2013.



Appointment of company secretary

With effect from 14 October 2013 Mrs Jenny Etchells has been appointed as company secretary, replacing Ms Giordana Verga who resigned, effective 30 September 2013.
07-Oct-2013
(Official Notice)
Shareholders are hereby advised that the basic earnings per share and headline earnings per share attributable to ordinary shareholders for the six months ended 31 August 2013 are expected to improve by more than 20%, as compared to those reported for the previous corresponding period.



At this stage, the Company is unable to quantify, with reasonable certainty, the expected interim financial results to be reported on. An updated trading statement will be released once the Company is able to quantify, with reasonable certainty, the expected range of the improvement in the financial results. The information in this trading statement has neither been reviewed nor reported on by the Company?s external auditors.

20-Sep-2013
(Official Notice)
Shareholders were advised of the resignation of Giordana Verga as Company Secretary with effect from 30 September 2013.



A further announcement will be made as soon as a new Company Secretary has been appointed.
21-Aug-2013
(Official Notice)
Shareholders were hereby informed that Mr Anthony Spanjaard has been appointed as a director to the board of directors of Nutrition with effect from Wednesday, 21 August 2013.
14-Aug-2013
(Official Notice)
Shareholders are referred the announcement dated 14 June 2011 wherein shareholders were advised that Nutrition (at the time known as Imuniti Holdings Ltd.) had entered into a manufacturing agreement with Edge to Edge Global Investments Ltd. ("E2E"), in terms of which, inter alia, the Company has the exclusive right to manufacture the Imuniti Nutritional Supplement Combo Pack ("INSCP") on behalf E2E ("the Supply Agreement").



Further to the above, shareholders are advised that the Company has entered into mediation and arbitration proceedings with E2E, as provided for in the Manufacturing Agreement, in relation to the non-payment of monies due to Nutrition by E2E for the previous manufacture of INSCP's ("the Dispute").



As communicated to shareholders in the Annual Integrated Report 2013, the INSCP is still a product which could create opportunities for the Company in the future, however the Company's focus remains with its core businesses, being the Nutrition Foods Division and the Pharmaceutical Division. The Manufacturing Agreement in its current state and/or the settlement of the Dispute (which does not affect the existence of the Manufacturing Agreement) are both currently immaterial to the Company's existing operations.



In addition to the above, shareholders are advised that certain members of the board of the Company ("the Board") have, in their personal capacities as shareholders of E2E (together with other shareholders of E2E), applied to the Kwazulu-Natal High Court, Durban, for permission to liquidate E2E ("the Application"). The Application will be heard on Thursday, 15 August 2013, the outcome of which is uncertain at this stage. In the event that the Application is granted by the Kwazulu-Natal High Court, Durban, same could affect the existence of the Manufacturing Agreement.



Neither the Dispute nor the Application are regarded by the Board as material price sensitive information in terms of section 3.4 of the JSE's Listings Requirements. However, in view of the historic relationship with E2E and the uncertainty regarding the Dispute and/or the Application, the Board deemed it appropriate to inform shareholders of the developments contained in this announcement. To the extent required, any further developments in this regard will be communicated to shareholders in due course.
05-Jul-2013
(Official Notice)
Shareholders are advised that, at the annual general meeting of shareholders of Nutritional Holdings held today, 5 July 2013, at 10h00 at 5 Sneezewood Lane, Glen Anil, Durban, all of the proposed ordinary and special resolutions, as contained in the notice of annual general meeting, were passed by the requisite majority of shareholders present and voting in person or by proxy.
03-Jun-2013
(Official Notice)
Shareholders were advised that the company's audited condensed annual financial statements for the year ended 28 February 2013, as audited by Grant Thornton, (whose modified report, containing an emphasis of matter on going concern and which is available for inspection at the company's registered office) as well as the notice of annual general meeting, has been dispatched to shareholders on 31 May 2013, and contains no modifications to the results which were announced on SENS on 24 May 2013.



Shareholders are further advised that the condensed results released on SENS on 24 May 2013 were extracted from the audited annual financial statements, but was not audited itself. The directors took full responsibility for the accuracy and preparation thereof.



Notice of annual general meeting

Notice was also given that the annual general meeting of Nutritional Holdings shareholders will be held at 5 Sneezewood Lane, Glen Anil, Durban at 10 am on Friday, 5 July 2013, to transact the business as set out in the notice of the annual general meeting. The annual integrated report 2013 is available at the company's registered office or on its website, http://www.nholdings.co.za/
29-May-2013
(Official Notice)
The JSE advised that the auditors report of Nutrition's Audited Provisional Results for the year ended 28 February 2013 contains a modification. Shareholders are advised to refer to the provisional results to ascertain the exact nature of the modification. Accordingly, the company's listing on the trading system will continue to reflect an "E" annotation to indicate the modification. The annotation will be removed when the company's auditor's report no longer contains a modification.
24-May-2013
(C)
Revenue declined to R34.2 million (R41.2 million). A net attributable loss of R13.4 million (profit of R2.6 million) was made. In addition, the headline loss per share widened to 0.41cps (loss of 0.35cps).



Outlook

After Rob Etchells joining the group as CE in December 2012 the management team has instituted a fresh "hands-on" approach and expects that its current turnaround programme will see the group return to profitability in due course. The new strategy of a dual focus, being a supplier to "end users" as well as that of a 3rd party contract manufacturer, to other leading brands, should result in an improvement in sales levels with the associated economies of scale coming to the fore at the Nutrition factory. Furthermore, focus is being placed on gross margins at Impilo via the introduction of additional contract manufacturers.



The Imuniti Nutritional Supplement Combo Pack is still a product which could create opportunities for the company in the near future, however the slower than anticipated progress with product development as well as the clinical trials has forced management to go back to its roots and focus on its core businesses.
06-May-2013
(Official Notice)
Accordingly shareholders were advised that the company expects a loss per share of between 0.87 and 0.91 cents per share, compared to earnings of 0.2 cents per share in the previous corresponding reporting period. Headline earnings per share is not expected to vary by more than 20%.



In the previous corresponding reporting period the company reversed a portion of the impairment of the intangible asset relating to the distribution rights of the Imuniti Nutritional Supplement Combo Pack as they had received orders and produced this product at that time. Further anticipated orders did not materialise and as a result the R7.2 million has once again been impaired. Had this impairment reversal and subsequent impairment not been done, the earnings per share compared to the previous corresponding reporting period would be below the 20% variance disclosure requirement.



Shareholders are hereby advised that the company is currently in the process of finalising the results for the year ended 28 February 2013. The results for the year ended 28 February 2013 are expected to be published on or about 31 May 2013.
03-May-2013
(Official Notice)
In compliance with paragraph 3.59 (c) of the Listings Requirements of the JSE Limited and the announcement published on SENS on 13 March 2013 regarding the appointment of Mr Anthony Richard Pinfold (Tony) as non- executive director, shareholders are advised that Tony has been appointed a member of the Audit and Risk Committee with effect from 3 May 2013.
13-Mar-2013
(Official Notice)
Shareholders were informed of the following changes to the board of directors of Nutritional Holdings with effect from Tuesday, 12 March 2013.



The appointment of Mr Anthony Richard Pinfold as a non-executive director.
27-Feb-2013
(Official Notice)
Shareholders are advised that, in terms of a general authority to issue shares for cash granted to the directors of the company at the annual general meeting held on Thursday, 28 June 2012, the Company has issued 390 000 000 (three hundred and ninety million) ordinary shares for cash, representing 25.70% of the issued ordinary share capital of the company net of treasury shares, at an issue price of 1.97 cents per ordinary share (Issue Price) to Pop Up Trading 39 Pty Ltd (Pop Up Trading) being a public shareholder as defined in the Listings Requirements of the JSE Limited (Listings Requirements). Pop Up Trading is a party related to Mr. Tony Pinfold (Mr. Pinfold) who is a current shareholder of the Company.



The Issue Price reflects:

*a discount of 7% (seven Percent) for Nutritional Holdings? ordinary shares on the JSE for the 30 (thirty) trading days prior to 13 February 2013 being the date on which the negotiations regarding the Cash Issue were entered into; and

*a premium of approximately 7% (seven Percent) for Nutritional Holdings? ordinary shares on the JSE for the 30 (thirty) trading days prior to 25 February 2013 being the date on which the board of directors of the Company resolved to issue the shares.

*The total consideration to be paid by Pop Up Trading to the Company for the shares issued is R7 700 000 (seven million seven hundred thousand rand).

*The funds raised by the Company pursuant to the Cash Issue for Cash will be applied towards working capital and expansion of operations.
19-Feb-2013
(Official Notice)
Shareholders were informed that Messrs Jan Daniel Louw and John Christian Ellis have resigned from the board of directors of Nutritional Holdings effective 18 February 2013.
08-Feb-2013
(Official Notice)
Shareholders are advised that the company intends to pursue a capital raising exercise, the aim of which is to sufficiently re-capitalise the company to enable it to expand its business operations and pursue a strategic long-term growth path. It is anticipated that the capital raising exercise will either be in the form of a rights offer or a claw back offer. The board of directors of the company is in the process of assessing which of the two options would prove most beneficial to the company. Shareholders are advised that a further announcement regarding the abovementioned capital raising exercise will be made in due course wherein shareholders will be informed of the progress made and the outcome of the board's deliberations on the matter.
30-Nov-2012
(C)
Revenue decreased to R17.5 million (R22.8 million). Gross profit declined to R9.4 million (R10.4 million). Operating loss before interest widened to R3.7 million (loss of R2.2 million). A net attributable loss of R3.9 million (profit of R5.8 million) was made. In addition, the headline loss on a per share basis more than doubled to 0.26cps (loss of 0.12cps).



Prospects

The first half of the financial year has been particularly challenging for the group with revenue dropping as a result of pressure on the low margin tender based market. Consequently the group's results show a significant drop in earnings. This has prompted a review of the management structure as well as its core markets. To this end the board has appointed a new CEO, to oversee the "turnaround" of the group's operations, effective 30 November 2012. The incumbent CEO has been working closely with the board over the past two months formalising a "turnaround" strategy. Going forward the group will be refocusing its operations towards the FMCG wholesale market as well as reviewing its product range.



The effect of these changes is expected to have a positive influence in the group's performance in the next 12 to 18 months. The process of rationalisation and re-focusing of the group's core businesses will necessitate the raising of capital to fund the restructure process. The finalisation of this process is expected by the end of the current financial year.
30-Nov-2012
(Official Notice)
Shareholders were informed that Mr Rob Etchells has been appointed as the chief executive officer of Nutritional Holdings with effect from 30 November 2012.
16-Nov-2012
(Official Notice)
Shareholders were advised that further to the Trading Statement released on SENS on 5 November 2012, the company is expecting earnings per share for the six months ended 31 August 2012 to be between 143% and 163% lower compared to the earnings per share for the previous corresponding period and headline earnings per share for the six months ended 31 August 2012 to be between 107% and 127% lower compared to the headline earnings per share for the previous corresponding period.



The financial results for the six months ended 31 August 2012 are expected to be released on or about 30 November 2012.
05-Nov-2012
(Official Notice)
Shareholders were advised that the company is expecting earnings and headline earnings per share, for the six months ended 31 August 2012, to be more than 20% lower compared to the earnings and headline earnings per share for the previous corresponding period. An updated trading statement will be released once the company is able to quantify, with reasonable certainty, the expected range of the decline in the financial results.
21-Sep-2012
(Official Notice)
Shareholders are hereby advised that, following the announcement on SENS on 13 July 2012, Mr John Ellis and Mr Jan Louw have been appointed as members to the Audit and Risk Committee. In addition, shareholders are hereby informed that Mr. Henk van der Merwe has resigned as chief executive officer and director from the board of directors of Nutritional Holdings with effect from 31 October 2012.
13-Jul-2012
(Official Notice)
The board appointed Mr. John Ellis and Mr. Jan Louw as non-executive directors with effect from 12 July 2012.
28-Jun-2012
(Official Notice)
Shareholders are advised that, with the exception of Ordinary Resolution 9 insofar the placement of the unissued ordinary shares under the control of the directors for purposes of the share option scheme which was withdrawn at the AGM, all the ordinary and special resolutions proposed in the Notice of Annual General Meeting were passed by the requisite majorities of shareholders present and represented by proxy and being entitled to vote at the AGM, which meeting was held on 28 June 2012 at 10h00.
12-Jun-2012
(Official Notice)
The JSE advised that the audit opinion on the above company's annual financial statements for the year ended 29 February 2012 contains a modification. Shareholders are advised to refer to the annual financial statements to ascertain the exact nature of the modification. Accordingly, the company's listing on the JSE TRADELECT system will be annotated with an "E" to indicate the modification. The annotation will be removed when the company's auditor's report no longer contains a modification.
31-May-2012
(Official Notice)
Shareholders are advised that the company's 2012 integrated report for the year ended 29 February 2012 as audited by Grant Thornton, whose unqualified report is available for inspection at the company's registered office, is being dispatched to shareholders today, and contains no modifications to the group results which were announced on SENS on 23 May 2012.



Emphasis of matter

Shareholders are advised that the audit opinion on the company's annual report for the year ended 29 February 2012 is unqualified but includes an emphasis of matter which refers to the fact that the company had accumulated losses of R74.793 million (2011: R91.379 million) and that the group had accumulated losses of R88.181 million (2011: R90.8 million).



Notice of annual general meeting

Notice is hereby given that the annual general meeting of Nutritional Holdings shareholders will be held at the Durban Country Club, 101 Isaiah Ntshangase Road, Durban at 10 am on 28 June 2012, to transact the business as set out in the notice of the annual general meeting contained in the integrated report.
23-May-2012
(C)
Revenue declined to R41.1 million (R46.7 million). Gross profit decreased to R20 million (R21.7 million). However, net attributable profit for the year jumped to R2.6 million (R1.7 million). However, a headline loss per share of 0.35c (earnings of 0.14cps) was recorded.



Annual general meeting

Shareholders were advised that it is anticipated that the company's integrated annual report (incorporating the audited annual financial statements) will be distributed on or before Thursday, 31 May 2012 which contains the notice of the annual general meeting to be held at the Durban Country Club on Thursday 28 June 2012 at 10:00.
17-May-2012
(Official Notice)
Further to the trading update issued on 9 May 2012, shareholders are advised that the company expects to report an earnings per share for the year ended 29 February 2012 to be between 0.19 cents and 0.22 cents per share compared to a earnings per share of 0.15 cents for the year ended 28 February 2011. All other information referred to in the 9 May 2012 trading update remains unchanged. Shareholders are advised that the company is currently in the process of finalising the results for the year ended 29 February 2012. The company's results for the year ended 29 February 2012 is expected to be published on or about 24 May 2012.
09-May-2012
(Official Notice)
The board of directors therefore wishes to advise shareholders that the company expects to report a headline loss per share for the year ended 29 February 2012 to be between 0.33 cents and 0.35 cents per share compared to a headline earnings of 0.14 cents for the year ended 28 February 2011. The results for the previous corresponding period were affected by the IFRS requirements relating to the recognition of deferred tax assets on estimated tax losses which were recognised for the first time during the 2011 period. This recognition of deferred tax assets on estimated tax losses amounting to R7.6 million, which increased the headline earnings per share for the year ended 29 February 2011 from a loss of 0.54 cents to earnings of 0.14 cents per share. Shareholders are advised that the company is currently in the process of finalising the results for the year ended 29 February 2012. The company's results for the year ended 28 February 2012 is expected to be published on or about 24 May 2012.
30-Apr-2012
(Official Notice)
Jenny Etchells will be resigning as FD of the company effective 31 May 2012 but will remain as a non-executive director on the board. Clayton Angus, currently a non-executive director will take up the position as financial director of the company with effect from 1 June 2012.
02-Apr-2012
(Official Notice)
Further to the cautionary announcement released on SENS on 28 November 2011 and its renewal on 12 January 2012, 7 February 2012 and 20 March 2012, the board of directors of Nutrition ("the board") advised that an in-principle agreement has been reached with the IDC for the funding for the Imuniti Nutritional Supplement Combo Pack ("ISCP") Project ("the funding agreement"). The funding agreement is subject to signing of legal agreements and the fulfilment of certain conditions precedent.



As mentioned in the announcement dated 7 February 2012, an application was made to the IDC for the funding of the ISCP project together with Edge to Edge Global Investments Limited ("E2E"). A phased approach has now been taken for the funding of the project and it has been agreed that the immediate requirements of funding to ensure the success of this project would be for: * the cost of the setting up of distribution outlets by E2E; and * the cost of the clinical Phase II trials to be carried out by E2E on the ISCP for reaffirmation of previous trials on the product.



The manufacturing capacity of the Nutrition plant is sufficient in the short term and allows for the supply of the ISCP in the interim. Accordingly, the upgrade of the manufacturing facilities by Nutrition will be done at a later stage as and when the demand for the ISCP product has increased. The funding by the IDC is therefore being routed directly to E2E with IDC committing to an initial R100 million to E2E linked to an equity transaction by E2E with a BBBEE partner, namely Makana Investment Corporation ("MIC"). MIC is a company initiated by the formation of the Ex-Political Prisoners Committee, a committee formed as a result of a call by Nelson Mandela.



The board is pleased with this outcome as it has a direct beneficial effect on the manufacturing and supply of the ISCP by Nutritional Holdings to E2E in terms of the exclusive manufacturing agreement signed in June 2011. The same staged approach to the funding via the Department of Trade and Industry is being adopted with regards to the Industrial Participation Programme. Negotiations are still ongoing by E2E with Obligors in this programme.



Cautionary

Shareholders of Nutritional Holdings are referred to the renewal of cautionary announcement dated 20 March 2012, and are advised that caution is no longer required to be exercised by shareholders when dealing in the company's securities.
20-Mar-2012
(Official Notice)
Shareholders are referred to the previous cautionary announcements dated 12 January 2012 and 7 February 2012 and are informed that negotiations regarding the DTI Application and the IDC Application (as referred to therein) remain ongoing. As the outcome of the abovementioned applications may have material effect on the price of the company's securities, shareholders are therefore advised to continue exercising caution when dealing in the company's securities until a further announcement has been made regarding either of the DTI Application or the IDC Application.
07-Feb-2012
(Official Notice)
Shareholders are referred to the previous cautionary announcement dated 12 January 2012. Further to the aforementioned announcement, shareholders are informed that during the latter part of 2011, an application was made together with Edge to Edge Global Investment Ltd ("E2E") to the National Industrial Participation Secretariat ("IPS") of the Department of Trade and Industry ("DTI") for the funding of the Imuniti Nutritional Supplement Combo Pack ("ISCP") Project ("the DTI Application"). This application was made following the positive clinical trial results on the ISCP as announced on SENS on 23 March 2011.



Nutrition manufactures the ISCP for E2E, the owners of the intellectual property related to the ISCP, pursuant to the exclusive manufacturing agreement concluded with E2E as announced on SENS dated 14 June 2011. The DTI Application was made in order to fund the following:

* the upgrade of the manufacturing facilities of Nutritional Holdings in order to meet the increase in demand of the ISCP when the distribution of the ISCP escalates to a point where the facilities are not able to meet the demand;

* the cost of the medical Phase II trials to be carried out by E2E on the ISCP for reaffirmation purposes; and

* the cost of setting up distribution outlets.



Written confirmation has been received from the IPS that on 15 January 2012 a decision was made by the Industrial Participation Internal Control Committee approving the concept in principle, which allows negotiations with obligors to commence. In addition to the DTI Application, application was also made to the Industrial Development Corporation ("the IDC Application") last year in conjunction with E2E for the funding of the ISCP project. The IDC has confirmed that they have completed their basic assessment of the application and any further developments in this regard will be communicated to shareholders as and when they arise.



Shareholders are therefore advised to continue exercising caution when dealing in the company's securities until a further announcement has been made regarding either of the DTI Application or the IDC Application.
28-Nov-2011
(Official Notice)
Shareholders were advised that the company has entered into negotiations which, if successfully concluded, may have a material effect on the price at which the company's securities trade on the JSE Limited. Accordingly, shareholders are advised to exercise caution when dealing in the company's securities until a further announcement is made.
18-Nov-2011
(C)
Revenue for the interim period ended 31 August 2011 fell to R24.2 million (2010: R26.5 million). Operating loss narrowed to R2.2 million (2010: loss of R2.4 million), while profit for the period grew to R5.8 million (2010: loss of R2.8 million). Furthermore, headline loss per share lowered to 0.12cps (2010: loss of 0.26cps).



Dividend

No dividend was declared.
17-Nov-2011
(Official Notice)
The board of Nutrition has resolved to authorize Nutrition to provide financial assistance to persons who are related or inter-related to Nutrition. Financial assistance for the purpose of this resolution, refers to loans to subsidiary companies as well as the cross suretyship by and between subsidiary companies.
08-Nov-2011
(Official Notice)
Further to the trading statement dated 22 September 2011, shareholders are advised that for the six months ended 31 August 2011, the earnings per share attributable to ordinary shareholders is expected to have improved between 348% and 368% from the loss of 0.26 cents per share for the six months ended 31 August 2010 and the headline loss per share is expected to have improved by between 44% and 64% from the loss of 0.26 cents per share for the six months ended 31 August 2010. The financial results for the six months ended 31 August 2011 are expected to be released on or about 22 November 2011.
14-Oct-2011
(Official Notice)
The company's shareholders approved two special resolutions which have been detailed below. The consent process was conducted by way of a written round robin resolution which was explained by the directors to the relevant shareholders, and subsequently signed. The rationale for having passed the special resolutions as per this announcement by way of Section 60 of the Act was to rectify certain technical difficulties raised by CIPC with regards to two special resolutions, one of which being the conversion of the company's share capital from shares with par value to shares with no par value and the second being the increase in the authorised share capital, as previously approved by shareholders in general meeting on 24 June 2011 ("the general meeting") and as per the announcement released on SENS on 15 August 2011. The aforementioned resolutions are required to give effect to the specific issues of shares for cash approved by shareholders at the general meeting ("the specific issue"). In addition, Section 60(4) requires the company to notify all the shareholders of the results of the vote of these resolutions. Accordingly, the resolutions were voted on and passed unanimously following votes received by the requisite majority of 75.95% as required by the company's Memorandum of Incorporation.
22-Sep-2011
(Official Notice)
Shareholders were advised that the basic earnings per share and headline earnings per share attributable to ordinary shareholders for the six months ended 31 August 2011 are expected to improve by more than 20%, as compared to those reported for the previous period. At this stage, the company is unable to quantify, with reasonable certainty, the expected interim financial results to be reported on. An updated trading statement will be released once the company is able to quantify, with reasonable certainty, the expected range of the improvement in the financial results.
24-Aug-2011
(Official Notice)
Shareholders are referred to the announcement on SENS dated 10 June 2011, in terms of which it was announced that Mrs. Jenny Etchells was to assume the roles of company secretary and financial director of Nutritional Holdings following the resignation of Mr. Paul Fouche.



The board announce the appointment of Mrs. Giordana Verga as company secretary with effect from Wednesday 24 August 2011. The appointment of Giordana will allow Jenny Etchells to focus her efforts as full time financial director of Nutritional Holdings.

23-Aug-2011
(Official Notice)
Nutrition announced the appointment of Mr. Clayton Angus as an independent non-executive director of the board with effect from, Tuesday 23 August 2011.
22-Aug-2011
(Official Notice)
On 22 June 2011 Nutrition announced that it will be seeking an admission of its shares to trade on the AIM Market of the LSE ("the proposed AIM listing"). The company has now submitted its application to the South African Reserve Bank for approval of the intended process. During July 2011, the company visited potential advisors as well as the LSE and received positive feedback. The company is in the process of appointing its advisory team in the UK and would be making an announcement soon in this regard.
15-Aug-2011
(Official Notice)
15-Jul-2011
(Permanent)
Imuniti was renamed to Nutritional Holdings Ltd. on Monday, 18 July 2011.
08-Jul-2011
(Official Notice)
Shareholders are referred to the announcements dated 15 June 2011 and 1 July 2011 insofar the postponement of the salient dates for the change of name of the Company and conversion of its shares to no par value shares due to a delay in the registration with the change of name and other special resolutions with the Companies and Intellectual Properties Commission ("Cipcom").



Further to the above, shareholders are informed that the company has since received confirmation from Cipcom that the requisite special resolutions have been duly registered. Accordingly, the salient dates applicable to the change of name and the issuance of no-par value shares are as follows:

*Last date to trade under name "Imuniti Holdings Ltd" Friday 15 July 2011

*New shares listed and traded under new name "Nutritional Holdings Ltd", JSE Code NUT and ISIN ZAE000156485 Monday 18 July 2011

*Record date Friday 22 July 2011

*Issue of new share certificates and CSDP / broker accounts updated Monday 25 July 2011



Shareholders are further advised that share certificates in the name of Imuniti may not be dematerialised or rematerialised after Friday, 15 July 2011.
07-Jul-2011
(Official Notice)
The directors are pleased to advise shareholders that Imuniti will be a constituent of the JSE - AltX 15 index effective Friday 8 July 2011. The AltX 15 is an index that tracks the price performance of the 15 largest companies listed on the AltX.
04-Jul-2011
(Official Notice)
Shareholders are hereby advised that Imuniti has appointed PSG Capital (Pty) Ltd as designated advisor to the company with effect from 4 July 2011.

01-Jul-2011
(Official Notice)
Shareholders were advised that due to a delay in the registration with the Companies and Intellectual Properties Commission of the change of name of the company as well as other special resolutions, the salient dates for the change of name and conversion of shares to no par value shares has been postponed. New salient dates will be announced as soon as the special resolutions have been registered.
24-Jun-2011
(Official Notice)
Shareholders are advised that the ordinary and special resolutions proposed at the general meeting and annual general meeting of the company held at 10:00 and 10:30 respectively on 24 June 2011, were all passed by the requisite majority.
22-Jun-2011
(Official Notice)
Imuniti Holdings Ltd announce the appointment of Mr Treve Hendry as a non-executive director of the company with effect from 22 June 2011.
22-Jun-2011
(Official Notice)
Imuniti is pleased to announce that it intends to seek an admission of its shares to trading on the AIM Market of the London Stock Exchange ("AIM"). In order to pursue this listing, the company requires South African Reserve Bank ("SARB") approval. SARB approval will not be granted until such time as Imuniti shareholders have been notified of the company's intention to seek a dual listing on AIM. Therefore the purpose of this announcement is to notify shareholders and satisfy the SARB request, in order that the company may compile its Reserve Bank application and submit same, and once it has received SARB approval, proceed with the application for a dual listing. The company has not yet approached the London Stock Exchange nor AIM for approval for the proposed listing, and such approval has therefore not yet been granted.



The results of the clinical trials which were announced on SENS on 23 March 2011 has initiated various talks with AIDS funding organisations in addition to the already existing partnership that Edge to Edge Global Investments Limited ("E2E") has with the African Forum . Treatment for vast amounts of AIDS victims who live in Africa is being supported by these funding organisations. Imuniti Holdings Limited has signed an exclusive manufacturing agreement with E2E for the Imuniti Nutritional Supplement Combo ("ISCP") as per the announcement on SENS dated 14 June 2011, which is the product used in these clinical trials. The funding organisations will assist in the roll-out of the Distribution Units for the ISCP across South Africa initially. This will result in a large increase in the manufacture of the ISCP by the company and the working capital and capital expenditure required for this will be provided by the capital raised on the dual listing.



With the listing on AIM, the company believes it will benefit from improved access to global investors and global institutional support in the United Kingdom ("UK"). UK and European institutional investors are very strong supporters of African focused companies. The proposed AIM listing would allow UK and European shareholders to trade more freely in the company's shares.
20-Jun-2011
(Official Notice)
Shareholders are referred to the previous announcement in this regard dated 15 June 2011, and were advised that the resignation of Mr Paul Fouche as the company secretary of Imuniti is 14 June 2011, and not 14 July 2011 as previously stated.
15-Jun-2011
(Official Notice)
Shareholders are advised that a circular detailing a specific issue of shares for cash, amendments to the share incentive scheme of the company, amendments to the share capital of the company, the conversion of par value shares to no par value shares and a change of name of the company has been posted to shareholders of Imuniti. The general meeting convened in terms of this circular shall be held at 10:00am on Friday, 24 June 2011, at the Durban country club, Durban.



All salient dates and times in this regard are given below:

*Circular and notice of general meeting posted to Imuniti shareholders -- Thursday, 2 June 2011

*Declaration date for change of name -- Thursday, 2 June 2011

*Forms of proxy for general meeting of shareholders to be received by 10:00am on -- Wednesday, 22 June 2011

*General meeting of shareholders to be held at 10:00am on -- Friday, 24 June 2011

*Results of general meeting released on SENS -- Friday, 24 June 2011

*Finalisation date for change of name -- Friday, 1 July 2011

*Last day to trade under name "Imuniti Holdings Ltd" -- Friday, 8 July 2011

*New shares listed and traded under new name "Nutritional Holdings Ltd", JSE code NUT and ISIN ZAE000156485 -- Monday, 11 July 2011

*Record date -- Friday, 15 July 2011

*Issue of new share certificates (if share certificates in the name of Imuniti Holdings Ltd are received on or before 12:00pm on the record date) and CSDP/broker accounts updated -- Monday, 18 July 2011

*Share certificates in the name of Imuniti may not be dematerialised or rematerialised after -- Friday, 8 July 2011.



Shareholders are advised that the company secretary, Mr PHA Fouche has resigned effective 14 July 2011 and that JA Etchells will be appointed as company secretary effective 14 June 2011.
14-Jun-2011
(Official Notice)
Imuniti Holdings Ltd has signed an exclusive manufacturing agreement with regard to the Imuniti Nutritional Supplement Combo Pack ("ISCP`) with Edge to Edge Global Investments Limited ("E2E"). This agreement gives Imuniti the exclusive right to supply E2E the first million ISCP Packs per month and thereafter they have the right of first refusal on any further manufacturing of the ISCP Packs. This new agreement supercedes all other previous agreements between E2E and Imuniti where previously Imuniti only had the non-exclusive right to manufacture and sell the ISCP Pack in South Africa. Shareholders will be advised on further developments in this regard.
10-Jun-2011
(Official Notice)
Shareholders are advised that Mr Paul Fouche, the Financial Director of Imuniti, has resigned as a director and the company secretary of the company with effect from 13 June 2011. Mrs Jenny Etchells, a current non-executive director of Imuniti, shall assume the role of financial director and company secretary with effect from 13 June 2011.
03-Jun-2011
(Official Notice)
The JSE advised that the audit opinion on Imuniti's annual report for the year ended 28 February 2011 contains a modification. Shareholders were advised to refer to the annual report to ascertain the exact nature of the modification. Accordingly, the company's listing on the JSE TRADELECT system will be annotated with an "E" to indicate the modification. The annotation will be removed when the company's auditor's report no longer contains a modification. This announcement has been placed by the JSE in the interest of shareholders.
27-May-2011
(C)
Revenue decreased to R46.7 million (R53.6 million) and gross profit was maintained at R21.8 million (R21.8 million). Operating loss lessened to R4.3 million (loss of R8.6 million), while profit for the year attributable to ordinary shareholders turned around to R1.9 million (loss of R9.4 million). In addition, headline earnings on a per share basis was recorded at 0.17cps (loss of 0.99cps).



Dividend

No dividend has been declared.



Prospects

The board remains pleased with the progress that has been made in stabilising and turning around the nutritional foods and impilo businesses since the management changes to date. The Imuniti head office, which will move to Gauteng, will continue to operate on a considerably downsized basis until the group has stabilised fully and is ready to move into the next phase of its strategic development.
23-May-2011
(Official Notice)
Shareholders are referred to the announcement dated 4 March 2011, wherein it was announced that the BBE Family Trust, the Ellis Family Trust, the Molefe Family Trust and the Kingfisher Discretionary Trust had all signed agreements to subscribe for 100 000 000 ordinary shares in the issued share capital of Imuniti at a subscription price of 3 cents per share. Subsequent to the board meeting of the company on 17 May 2011, certain amendments were made to the agreements detailed above, and consequently, the BBE Family Trust and the Ellis Family Trust shall now subscribe for 190 000 000 ordinary Imuniti shares at 3 cents per share, and the Molefe Family Trust and the Kingfisher Discretionary Trust shall now subscribe for 10 000 000 ordinary Imuniti shares at 3 cents per share. The circular to shareholders in this regard is in the process of being amended for these changes, and shall be posted to shareholders shortly.

20-May-2011
(Official Notice)
Shareholders are advised that for the period ended 28 February 2011, the headline earnings per share will increase by between 110% and 130% and the earnings per share will increase by between 140% and 150%. The above information has not been reviewed or reported on by the group's external auditors.
12-May-2011
(Official Notice)
Shareholders were advised that for the period ended 28 February 2011, its headline earnings per share and earnings per share are expected to be more than 120% higher than the results for the comparative period. At this stage, the company is unable to quantify, with any degree of certainty, the expected basic and headline earnings per share for the year ended 28 February 2011 and more specific information will be provided to the shareholders as soon as there is a degree of certainty as to the range, within 20%, by which headline earnings per share and earnings per share will improve.
11-May-2011
(Official Notice)
The board announced the resignation of Mr Paul Fouche as financial director with effect from 31 July 2011. The company will advise shareholders of a new appointment once confirmed.
04-May-2011
(Official Notice)
Following the announcement on 23 March 2011, Edge to Edge Global Investments Ltd (E2E), the owners of the intellectual property related to the Imuniti Nutritional Supplement Combo Pack (ISCP) which Imuniti manufactures, have advised the following: A suitable application was submitted to the Financial Surveillance Department of the South African Reserve Bank through FirstRand Exchange Control, and Edge to Edge Global Investments Limited received an approval in terms of its submission for establishing companies offshore to deal with the international roll-out of the ISCP. The successful approval allows for active pursuance of offshore funding. This funding will provide the working capital required for Imuniti to manufacture ISCP based on the credit terms with E2E.
14-Apr-2011
(Official Notice)
Shareholders are referred to the announcements on SENS dated 23 September 2010 and 4 March 2011, respectively, in relation to the adjournment of the annual general meeting. The annual general meeting was held on 23 September 2010 and was adjourned due to queries raised by a representative of group of shareholders, in respect of certain special and ordinary resolutions. Subsequently, the board of directors has been reconstituted and a decision has been taken that the resolutions that were not dealt with at the previous annual general meeting will now be dealt with in the forthcoming general and annual general meetings, which dates will be announced in due course. Thus the annual general meeting held on 23 September 2010 is considered closed and will not be reconvened.
05-Apr-2011
(Official Notice)
Shareholders were advised that Grant Thornton will be appointed as the auditor of Imuniti with immediate effect. The audit committee has considered and confirmed the independence of Grant Thornton.
23-Mar-2011
(Official Notice)
Shareholders are referred to the cautionary announcement published on 14 March 2011. Imuniti manufactures the Imuniti Nutritional Supplement Combo (INSCP) Pack for Edge to Edge Global Investments Ltd (E2E), the owners of the intellectual property related to the Imuniti Pack. E2E have advised in a press release the following: A clinical trial was conducted on HIV positive patients. The clinical trial was conducted by Prof Luc Montagnier on the INCSPin conjunction with ARV therapy, conducted at the Centre Integre de Recherches Biocliniques d`Abidjan (C.I.R.B.A.), Cote d'Ivoire (under the auspices of UNESCO).



What was clearly observed on this first preliminary trial was the following:

Using the new biomarker developed by Professor Montagnier to measure the remaining viral DNA in the body after ARV treatment and also using the current standard of measurement namely PCR measurement, the following trend was observed:

*The control arm of ARV alone showed no change in any of the markers requested as per trial protocol.

*The ARV plus INSCP arm showed a substantial reduction in the viral DNA in 71% of the patients. Furthermore, PCR showed that 28% of the patients had viral DNA disappear after three months of INSCP treatment. This is the first time that this viral DNA has ever been impacted by a natural combination product.



The preliminary results justify further clinical trials with a larger number of patients. It is also envisaged to use INSCP in HIV positive naive patients not yet treated by ARVs.



Withdrawal of cautionary announcement

Shareholders are referred to the cautionary announcement issued on 14 March 2011, and are advised that they no longer need to exercise caution in dealing with the shares of Imuniti in relation to the prior cautionary announcement.
14-Mar-2011
(Official Notice)
Imuniti manufactures the Imuniti Pack for Edge to Edge Global Investments Ltd (E2E), the owners of the intellectual property related to the Imuniti Pack. E2E have advised that significant trial results relating to the pack will be announced shortly. This may have a material effect on the price of the company's shares and shareholders are advised to exercise caution when trading in Imuniti shares until such announcement is made public.
04-Mar-2011
(Official Notice)
20 Jan 2011 08:51:41
(Official Notice)
Shareholders are referred to the cautionary announcements dated 29 October 2010 and 09 December 2010. As detailed in the announcements, the company has moved forward in resolving the appointment of directors and going concern issues. Both these issues are in the process of being finalised and shareholders will be advised accordingly in due course. Shareholders are accordingly advised to continue to exercise caution when dealing in the Company's securities until a further announcement is made.

09 Dec 2010 11:42:22
(Official Notice)
Shareholder update

Shareholders are referred to the cautionary announcement dated 29 October 2010. As detailed in the announcement and annual report, the directors advised that the going concern of the group is dependent on, inter alia, the ability to raise additional capital through the issue of shares. Three directors of the company also resigned. It is noted that, due to the company only having one remaining director, the board will be unable to act until three new appointments are made. The company has moved forward in resolving the going concern issue.



The founder shareholders have provided funding and have agreed to assist the company through continued funding. It is expected that in early 2011 significant capital will be injected by the founding shareholders into the company which will ensure its continued viability. The company is further involved in negotiations with prospective non-executive directors and it is expected that all vacant board positions will be filled in early 2011.



Renewal of cautionary announcement

Accordingly, shareholders are advised to exercise caution when dealing in the company's securities until a further announcement is made.

09 Nov 2010 16:05:46
(Official Notice)
The board announced the resignation of Mr S R Bean, non-executive director and chairman of the audit committee with immediate effect. It is noted that, due to the company only having one remaining director, the board will be unable to act until three new appointments are made. In addition, the approval of the necessary shareholder resolutions is also still uncertain until approval at a reconvened special general meeting.
29 Oct 2010 11:45:37
(Official Notice)
As detailed in the company's annual report, the directors advised that the going concern of the group is dependent on, inter alia, the ability to raise additional capital through the issue of shares. As announced on SENS on 23 September 2010, at the AGM of the company, certain resolutions relating to shares being under the control of directors and the general authority to issue shares for cash have been deferred and a special general meeting will need to be reconvened to approve these resolutions. A consortium representing a majority of shareholders has indicated that it will not support the efforts of the current board to raise capital through the issue of shares unless certain directors resign. No specific reasons have been provided by these same shareholders, who were also asked to provide a nomination for replacement directors. To date no replacement directors have been put forward. Whilst the board of directors has made substantial progress in turning the company around, the company is still dependant on the injection of further funding through the issue of shares as highlighted in the company's 2009/2010 annual report. The resigning directors believe therefore that it is in the best interest of the company that they should resign on the expectation of an injection of funding and/or approval of the necessary resolutions. The board of directors announced the resignation of Messrs NP Lamble, Acting CEO and MR Gahagan, Independent Non-executive Chairman with effect from 31 October 2010.



It is noted that, due to the company only having two remaining directors, the board will be unable to act until two new appointments are made. In addition, the approval of the necessary shareholder resolutions is also still uncertain until approval at a reconvened Special General Meeting.



Cautionary announcement

Accordingly, shareholders are advised to exercise caution when dealing in the company's securities until a further announcement is made.
29 Oct 2010 11:31:25
(C)
Revenue dropped slightly to R26.5 million (R27.5 million), however, gross profit grew to R13.4 million (R11.2 million). Loss attributable to ordinary shareholders narrowed to R2.8 million (loss R6.2 million). Furthermore, headline loss per share was recorded at 0.26cps (loss of 0.68cps).



Dividend

No dividend was declared for the six month period.



Prospects

The board is pleased at this point with the progress that has been made in stabilising the company and re-focusing the company strategy and structure on the two underlying businesses. The Imuniti head office continued to operate with an extremely lean structure with available resources being directed into the underlying businesses in line with the company strategy. Despite the fact that there were no sales of the Imuniti Wellness Pack during the period, demand for the products and brands of the two underlying companies remains strong. There is still considerable spare capacity at the Nutritional Foods factory in Klerksdorp to take advantage of market opportunities that exist. However as reported previously in the company's annual report, the further injection of capital into the company is critical to ensure the success of the business in realising its full potential in the future.
22 Oct 2010 10:13:55
(Official Notice)
Shareholders are advised that Imuniti expects its loss per share and headline loss per share, for the six months ended 31 August 2010 to improve by between 55% to 75% compared to the six months ended 31 August 2009.
23 Sep 2010 16:18:36
(Official Notice)
Shareholders are advised that, at the annual general meeting of Imuniti held on Thursday, 23 September 2010, the resolutions relating to the approval of the annual financial statements, the re-election of Mr MR Gahagan as a director, directors' remuneration, directors' authority to approve the auditors' remuneration and the authority of the directors to deal with the appointment of auditors for the coming year were passed by the requisite majority of shareholders. Due to queries raised by a representative of certain shareholders, the remaining special and ordinary resolutions will be considered at a reconvened annual general meeting, notice of which will be sent to shareholders in due course, with further details and/or modifications as required.
03 Sep 2010 09:13:21
(Official Notice)
The JSE advised that the audit opinion on the above company's annual report for the year ended 28 February 2010 contains an "emphasis of matter" audit opinion. Shareholders are advised to refer to the annual report to ascertain the exact nature of the modification. Accordingly, the company's listing on the JSE tradelect system will be annotated with an "E" to indicate the modification. The annotation will be removed when the company's auditor's report no longer contains a modified opinion.
31 Aug 2010 10:18:02
(Official Notice)
The company advised that there was a minor amendment to the group's financial statements resulting from the audit of Imuniti for the year ended 28 February 2010. The headline earnings per share in the reviewed results as published on SENS on 27 May 2010 was a loss of 0.98 cents per share, whilst the final headline earnings per share reflected in the audited financial statements is a loss of 1.02 cents per share. The amendment was a result of a debtor being classified as not recoverable. An amount of R370 443 was written-off as a bad debt. Other than this amendment, the company confirms that there was no change between the reviewed results as published and the audited financial statements. The annual report has been posted to shareholders on 31 August 2010.



Notice of AGM

Notice was that the fourth annual general meeting of the members of Imuniti will be held in Durban at 12:00 on the 23 September 2010 at the Durban High School Old Boys Club, 20 Gainsborough drive Durban. Details of the proceedings and resolutions are contained in the aforementioned report.
01 Jun 2010 16:03:02
(Official Notice)
Shareholders and potential shareholders are advised that the board of directors recently became aware that a private placing document issued last year ("document") for a public unlisted company names Imuniti and two of its subsidiaries as its contracted manufacturer/s. Imuniti confirms that it has a non-exclusive manufacturing, marketing, sales and distribution agreement with this company. However, the value associated with this contract was impaired to R Nil in the annual financial statements for the year ended 28 February 2009 due to very low volumes being purchased under the contract.



The board has become aware that the document states that the Imuniti pack would be purchased from Imuniti at a price of R150, and believes that the document could possibly infer that Imuniti's turnover and volumes are well in excess of those being achieved and also what could possibly be achieved in the future based on existing capacity. The board would like to advise that it has had no input into the said document. Existing and potential investors are advised to rely only on information published by Imuniti on SENS or in circulars or annual financial statements issued by the company or its directors.
31 May 2010 12:10:26
(C)
Revenue for the year ended 28 February 2010 decreased to R53.6 million (2009: R60.5 million) . Gross profit fell to R21.8 million (2009: R30 million), while total comprehensive loss attributable to ordinary shareholders was lower at R8.6 million (2009: R54 million) . Furthermore, headline loss per share also decreased to 0.98cps (2009: 1.10cps) .



Dividend

No dividend was declared.



Prospects

The board remains pleased with the progress that has been made in stabilising and re-focussing the Imuniti businesses to date. In line with the strategy of focussing on the profitability and health of the two underlying businesses, the new position of managing director was created at Nutritional Foods. This has resulted in far higher levels of coordination and cooperation between the different elements of this business and a far greater strategic focus on the direct needs of the business. The factory still has considerable spare capacity and the impact of the expected increase in volumes on profitability will be considerable. The agreements between the Impilo businesses and Pac-Con have had the effect of eliminating the extensive losses that Impilo was previously incurring. It has provided the platform and the capacity to re-establish the Impilo range in the market place. In order to drive this process, a full time national sales manager for Impilo Marketing was appointed after year end. A major R10 million upgrade of the manufacturing facility was commenced by Pac-Con in December 2009 and is due for completion by June 2010. This will ensure that the factory is fully compliant with all Medicines Control Council ("MCC") regulations. The Imuniti head office will continue to operate on a considerably downsized basis until the group has stabilised fully and is ready to move into the next phase of its strategic development. As reported previously, the MCC phase one trials of the Imuniti wellness pack have been concluded and phase two trials are currently underway.
12 May 2010 11:11:50
(Official Notice)
The board of Imuniti wanted to clarify the events relating to the arrival of an investigation team from the South African Revenue Services ("SARS") at the company's head office in Durban on Tuesday 11 May 2010. The SARS team arrived at the Imuniti head office at approximately 08h30 on 11 May 2010 with a "warrant for search and seizure in terms of section 74D of the income tax act, act 58 of 1962, and section 57D of the value added tax act, act 89 of 1991" ("the warrant"). Six individual taxpayers (including some shareholders of Imuniti) were listed in schedule A of the warrant. Imuniti is listed as one of 36 entities in schedule B of the warrant whose premises the SARS team was entitled to enter and search for "evidence to any non compliance with the provisions of" the above acts. None of Imuniti's subsidiaries, directors, executives or staff is mentioned in the warrant. At no time were the South African police services present on the premises.



The Imuniti staff present co operated fully with the SARS team throughout the day in their investigation and provided them with all the information requested. It was absolutely clear that the SARS investigation related to the possible infringement of one of the tax acts on the part of one or more parties. The board is not aware whether the investigation into a "fraudulent investment scheme" involving a product for "HIV/Aids sufferers" as announced by the minister of finance Mr Pravin Gordhan in parliament on 11 May 2010, in any way relates to Imuniti Holdings Ltd. If so, the board is completely unaware of such a scheme or such an investigation. Imuniti trust that this clarifies the events, press speculation and announcements relating to the above matters that took place yesterday on 11 May 2010.
21 Apr 2010 08:58:32
(Official Notice)
The board of Imuniti Holdings announced that a five year non- exclusive manufacturing agreement has been entered into between Impilo Marketing (a subsidiary of Imuniti Holdings) and Pac-Con Pharmaceuticals in respect of the manufacture of the Impilo range of products and the Imuniti Wellness Pack. This agreement is effective as from 1 April 2010 and is essentially an extension of the previous one year agreement between the parties which has already brought considerable benefits to the Impilo Group.



Pac-Con Pharmaceuticals manufactures a wide range of personal care and other products for some of South Africa's major FMCG companies and they have proved to be an ideal manufacturing partner for Impilo. Pac-Con is currently, at its own expense, undertaking a major upgrade of the Impilo factory which will cost in excess of R10 million and which will ensure that the factory is fully compliant with all the relevant MCC requirements into the future. Both parties are in the process of obtaining the necessary MCC approval for the new manufacturing arrangement. Ownership of the product dossiers (product formulae) remains fully the property of Impilo in terms of this agreement. A further agreement between Impilo Drugs and Pac-Con Pharmaceuticals in respect of the rental (with an option to purchase) of the Impilo plant and equipment has also been concluded. The above two agreements provide a secure platform for the supply of the Impilo products and the Imuniti Wellness Pack on a highly cost effective basis into the future.
12 Apr 2010 08:46:30
(Media Comment)
Imuniti has finally disclosed the identity of it's new black economic empowerment partner as Pac-Con Research, a Durban-based third-party contract company. The AltX-listed pharmaceutical and nutritional foods company said on it's website that Pac-Con Research was it's key BEE shareholder. Information about the partner's shareholding of directorship were not revealed.
15 Mar 2010 09:53:06
(Official Notice)
Shareholders are advised that Imuniti expects its attributable loss per share for the year ended 28 February 2010 to improve by between 80% to 90% compared to the prior year and the headline loss per share for the same period to improve by up to 10%. The results for the period ended 28 February 2010 are expected to be published on SENS on or about 31 May 2010.
27 Nov 2009 14:42:24
(C)
Revenue declined to R27.5 million (R31.2 million). Gross profit decreased to R11.2 million (R17.3 million) and the net attributable loss widened to R6.2 million (loss of R3.2 million). The headline loss worsened to 0.68cps (loss of 0.38cps).





Prospects

The Impilo business units are already showing a significant improvement in performance and profitability and the prospects for this part of the company are very promising. The Nutritional Foods business is in the process of re-aligning itself to changed market and competitive environments. The factory is still operating well below its design capacity and increased volumes will have a significant impact on the efficiencies and profitability of this business.



There are considerable market opportunities for new products, smaller pack sizes of existing products and exports especially to other African countries The resources that are now available with the investment of R4 500 000 into Imuniti (as announced recently) will enable Nutritional Foods to effectively implement its realignment process and take full advantage of the many opportunities that exist for its products. The Imuniti head office structure has been significantly downsized and management resources have been directed at the structures of the underlying businesses. The MCC Phase 1 Trials of the Imuniti Wellness Pack have now been successfully concluded and ethical approval has been granted for Phase 2 of the Trials. Opportunities for the Pack remain huge on a continent where malnutrition and HIV/AIDS are daily realities for millions of people.
24 Nov 2009 15:10:47
(Official Notice)
Imuniti shareholders are advised that the company has raised R4 500 000 in capital through the issue of 150 000 000 ordinary shares at 3 cents per share. In addition to the recent announcements regarding the outsourcing of the pharmaceutical manufacturing, and the report on the first phase of the Medical Research Council's trials on the Imuniti Wellness Pack, this capital injection will enable Imuniti to take further advantage of the market opportunities that exist for its products. As can be seen from the pro forma financial effects below, this cash injection is expected to increase the net asset value of the company by 18%.



Issue for cash

At the annual general meeting of the company held on 23 September 2009, the requisite majority of shareholders approved an ordinary resolution authorising the directors to issue shares for cash in accordance with the Listings Requirements of the JSE Ltd ("the Listings Requirements"). As the issue of these shares represents an increase of more than 5% of the issued ordinary share capital of the company, the following disclosure is required in terms of section 11.22 of the Listings Requirements:

*150 000 000 ordinary shares in the company have been issued at a price of 3 cents per ordinary share;

*The issue price of 3 cents per share represents the volume weighted average price (less 10%) at which Imuniti shares traded during the 30 day period up to the date the agreement was entered into; and

*The shares have been issued to public shareholders as defined by the Listings Requirements.



Listing of the new shares

The JSE Ltd has granted approval for this transaction, and the shares will be issued on the 8 December 2009.
24 Nov 2009 11:14:51
(Official Notice)
Shareholders are advised that Imuniti expects its fully diluted loss and headline loss per share for the six months ending 31 August 2009 to be - 0.68 cents and -0.68 cents respectively as compared to the loss and headline loss per share, on a fully diluted basis, of -0.38 cents and -0.38 cents respectively reported for the six months ending 31 August 2008.
11 Nov 2009 17:12:27
(Official Notice)
Further to the SENS announcement made on the 10 June 2009 in connection with the MRC trials, the directors are pleased to advise shareholders that the group has received the full report from the MRC regarding Phase I of the clinical trials conducted on the Imuniti wellness pack, a herbal-nutritional supplement with putative immune-modulating properties ("the wellness pack"). The directors reported that Phase II of the clinical trials has been approved by the MRC's ethics committee.
03 Nov 2009 13:58:23
(Official Notice)
Imuniti shareholders are advised that the company has raised R2 098 372 in capital through the issue of 61 123 182 ordinary shares at 3,5 cents per share. Imuniti previously reported that 171 428 571 ordinary shares were going to be issued to a BEE company. However, due a building accident at the BEE company's factory, only 55 044 200 shares were issued to this company. The accident resulted in the need to invest additional capital directly into the Impilo Drugs factory to significantly upgrade this facility. Imuniti has formed a strategic alliance with this company which is a long established, reputable manufacturer of personal and home care branded products with a factory that is ISO 9000:2000 rated. In addition Impilo has entered into a manufacturing subcontract agreement with this party to manufacture the full range of Impilo products. This has led to a significant increase in the sales volumes of these products.



Issue for cash

At the annual general meeting of the company held on 23 September 2009, the requisite majority of shareholders approved an ordinary resolution authorising the directors to issue shares for cash in accordance with the Listings Requirements of the JSE Ltd ("the Listings Requirements"). As the issue of new shares represents more than a 5% increase in the issued ordinary share capital of the company, the following disclosure is required in terms of section 11.22 of the Listings Requirements:

*61 123 182 ordinary shares in the company have been issued at a price of 3.5 cents per ordinary share;

*The issue price of 3,5 cents per share represents the volume weighted average price (less 10%) at which Imuniti shares traded during the 30 day period up to the date the agreement was entered into; and

*The shares have been issued to public shareholders as defined by the Listings Requirements.
23 Sep 2009 15:28:34
(Official Notice)
Resolutions proposed at the Imuniti AGM were passed unanimously with the exception of the resolution relating to the retiring by rotation and re-election of JJ Barnard which was withdrawn due to him not being available for re-election.
28 Aug 2009 16:24:08
(Official Notice)
The company advises that there was a minor amendment to the group's Financial Statements resulting from the audit of Imuniti for the year ended 28 February 2009. The headline earnings per share in the reviewed results as published on SENS on 29 May 2009 was a loss of 1.13 cents per share, whilst the final headline earnings per share reflected in the AFS is a loss of 1.10 cents per share. Other minor classification changes were as follows, but these did not have any effect on the earnings as reported:



Balance Sheet:

There was a re-allocation of R38 748 increasing trade and other receivables and reducing pre-payments.



Income Statement:

Operating Expenses were reduced by R239 985 and this amount was reallocated to Impairment of Loan (R32 877) and Impairment of Goodwill (R207 108)



Cash Flow:

There was a re-allocation of R134 197 between cash flow from financing to cash generated from operations. Other than these amendments, the company confirms that there was no change between the reviewed results as published and the AFS.



The annual report has been posted to shareholders on 28 August 2009.



Notice is hereby given that the third AGM of the members of Imuniti will be held in Durban at 12:00 on the 23 September 2009 at the Durban High School Old Boys Club, 20 Gainsborough Drive, Durban. Details of the proceedings, and resolutions are contained in the aforementioned report.
10 Jun 2009 16:23:37
(Official Notice)
Shareholders are advised that we have received the following communication from the South African Medical Research Council, regarding the Phase I of the clinical trials on the Imuniti Wellness Pack, which is a Herbal-Nutritional supplement with putative immune-modulating properties, as previously reported: "Results: Preliminary narrative results showed no toxicity and no side effects reported by any of the participants. The results are now being statistically reviewed for significances. Conclusion: The study was a success and a full report will be written. The IKS wish to apply for a Phase II controlled clinical trial of this product"



What is of significance is that the Phase II of the trial has been approved by the MRC's ethics committee. Imuniti quoted from the letter received from the MRC: The next study, which is a Phase II placebo controlled efficacy study, to be conducted in KwaZulu-Natal in the VCT centres has been granted ethical approval. This study will recruit 100 HIV positive participants per site from the rural, and semi-urban and an urban VCT site.
01 Jun 2009 16:35:57
(Official Notice)
Mr Mike Mantel has resigned as Financial Director and company secretary with effect from 31 May 2009 Shareholders are further advised that, the current CEO, Mr Paul Fouche will take over the role of Financial Director and company secretary with immediate effect and Mr Neil Lamble has been appointed as Acting Chief Executive Officer with effect from 1 June 2009 until a further appointment has been made.
29 May 2009 10:27:19
(C)
Sales have decreased by 12% as compared the twelve month financial period ended 29 February 2008 to R60.5 million (R68.8 million). The net attributable loss for the year more than doubled to R54.5 million (loss of R25.5 million). However, the headline loss narrowed to 1.13cps (loss of 1.60cps).



Outlook

The board is mindful that the increased level of macro-economic uncertainty over the last few months has created a challenging trading climate that will impact on the group. The group however remains committed to focusing on its core capabilities and will continue to improve its performance with a shift of focus to the marketing, distribution and sales of specific products to selected target markets.



The Nutritional Foods business can capture additional market share through aggressive pricing, revised trading terms and conditions and growth incentives. A new managing director has recently been appointed which will result in a much more focused approach to this business. In respect if Impilo Drugs, a management contract has been entered into to manage the manufacturing of this business. The contract is with a long established, successful manufacturing concern in a similar industry. This will enable Impilo to focus on the sales and distribution of the Impilo brands.
28 May 2009 13:47:19
(Official Notice)
Imuniti is currently preparing its results for the year ended 28 February 2009 and the company's auditors are currently auditing these results. Imuniti's directors believe that in terms of IAS36 - Impairment of Assets, Imuniti will need to impair its goodwill and intangible assets of the company following a process of assessment by the directors and review by the auditors on the carrying value of its goodwill and intangible assets. The quantum of the impairment is approximately R44.8 million. This is the biggest contributor to the change in the earnings per share. Shareholders are advised that Imuniti expects its fully diluted earnings and headline earnings per share, for the year ending 28 February 2009 to be -6.32c and -1.13c per share as compared to the earnings and headline earnings, on a fully diluted basis, of -3.38c and -1.60c reported for year ended 29 February 2008. Headline earnings are not affected by impairments to goodwill and intangible assets. The financial information in this trading statement has not been reviewed or reported on by Imuniti's auditors.
25 May 2009 10:35:18
(Official Notice)
Shareholders are advised that Grindrod Bank resigned as designated advisor to Imuniti with effect from 31 May 2009 and Arcay Moela Sponsors (Pty) Ltd will assume this role with effect from 1 June 2009.
13 Mar 2009 12:41:31
(Official Notice)
Imuniti shareholders are advised that the company has entered into agreement with a qualifying black economic empowerment company to raise R6 000 000 in capital by the issue of 171 428 571 ordinary shares at 3.5 cents per share. The BEE investor will add significant value to Imuniti from a business perspective in that it is a long established, reputable manufacturer of personal and home care branded products with a factory that is ISO 9000:2000 rated. Its customers include multi-nationals. The investor will have board representation in the form of one non-executive director.



Issue for cash

At the annual general meeting of the company held on 28 August 2008, the requisite majority of shareholders approved an ordinary resolution authorising the directors to issue shares for cash in accordance with the listings requirements of the JSE Ltd. As the issue of new shares represents a 19.5% increase in the issued ordinary share capital of the company, the following disclosure is required in terms of section 11.22 of the listings requirements:

* 171 428 571 ordinary shares in the company will be issued at a price of 3.5 cents per ordinary share.

* The issue price of 3.5 cps represents the volume weighted average price at which Imuniti shares traded during the 30 day period up to and including 26 February 2009, being the date on which the issue price was agreed upon by the directors.

* The shares will be issued to public shareholders as defined by the listings requirements.



Conditions Precedent

The general issue of shares for cash is conditional upon:-

*Settlement of the full R6 000 000 by not later than 31 July 2009.

*The relevant regulatory approvals.



Withdrawal of Cautionary

Shareholders are referred to the cautionary announcement issued by the company on 5 March 2009 and are advised that they no longer need to exercise caution in dealing with the shares of Imuniti
05 Mar 2009 15:55:47
(Official Notice)
Shareholders are advised that the company is currently involved in negotiations which could have a material effect on the price of Imuniti's shares. Shareholders are therefore advised to exercise caution in dealing with the shares of Imuniti until such time that a further announcement is made.
02 Feb 2009 14:09:12
(Official Notice)
Mr H A K Slabbert, has resigned as director of Imuniti with effect from 31 January 2009.
19 Dec 2008 14:14:28
(Official Notice)
Mr Johan Barnard has resigned as an executive director with effect from 31 December 2008. Mr Barnard will remain on the board as a non-executive director.
24 Nov 2008 15:46:03
(C)
Revenue declined to R31.2 million (R36.1 million). Gross profit decreased to R17.3 million (R18.6 million) and the loss attributable to ordinary shareholders narrowed to R3.2 million (loss of R5.3 million). In addition, the headline loss per share improved slightly, to 0.38cps (loss of 0.71cps).



Withdrawal of cautionary

Further to the cautionary announcement dated 16 October 2008, shareholders were advised that Imuniti has discontinued the negotiations referred to which could have had a material effect on the share price of Imuniti shares. Shareholders no longer need to exercise caution when dealing in Imuniti shares.



Outlook

The board is mindful that the increased level of macro-economic uncertainty over the last few months has created a challenging trading climate that will impact on the company. The company however remains committed to focusing on its core capabilities and will continue to improve its performance with a shift of focus to the marketing, distribution and sales of specific products to selected target markets. The Nutritional Foods business can capture additional market share through aggressive pricing, revised trading terms and conditions and growth incentives. This can be achieved as Nutritional Foods is trading over breakeven point and the factory is running below its design capacity.



The field work regarding the Medicine Research Council("MRC") trials on the Imuniti Wellness Pack has been completed and we are currently awaiting the official statistics and report from the MRC. Management is currently investigating the introduction of a direct marketing network that could have a significant positive impact on the group. At present 38% of natural and complementary medicines in South Africa are being distributed through direct marketing channels. Management will vigorously investigate this avenue. In addition Imuniti is investigating the export market, and the launch of a "monthly food pack" which could address the current food shortages that South Africa is faced with.
14 Nov 2008 14:21:07
(Official Notice)
The board of directors of Imuniti wish to advise shareholders that the loss and headline loss per share for the six months ended 31 August 2008 is expected to decrease by between 40% and 60% from the loss of 0.71cps reported for the six months ended 31 August 2007. The financial information in this trading statement has not been reviewed or reported on by Imuniti's auditors. Imuniti will release its financial results for the six months ended 31 August 2008 towards the end of November 2008.
24 Oct 2008 15:34:08
(Official Notice)
Shareholders are advised that Grindrod Bank Ltd has disposed of its minority interest in Exchange Sponsors (Pty) Ltd and has been approved by the JSE Ltd as designated advisors. Grindrod Bank will be assuming the role of the company's designated advisor with effect from 1 November 2008. Exchange Sponsors (Pty) Ltd will continue to act as Imuniti's designated advisor until 31 October 2008.
24 Oct 2008 09:57:03
(Official Notice)
Imuniti is pleased to advise shareholders of the following board appointments:

* Mr M R Gahagan as an independent non-executive director and chairperson. Mr Gahagan has a BComm (Hons) from Rhodes University and is a Chartered Accountant. He has vast experience in the listed company environment, having held various executive and non-executive directorships of listed companies and having been CEO of two listed companies. He is Chief Executive Officer of ARCAY Private Financial Services and has a strong focus on developing and financing entrepreneurial based businesses. He is a founder and director of Rifumo Investment Holdings (Pty) Ltd, and a non-executive director of IFCA Technologies Ltd and Sanyati Holdings Ltd.

* Mr S Bean as an independent non-executive director. Mr Bean has a B. Comm (Hons) (Accounting) degree as is a Chartered Accountant. He was a senior partner and director at audit firm BDO Spencer Steward Kzn Inc for 5 years. Currently he is a consultant with BDO Spencer Steward as well as an independent business and tax advisor. In addition he has a wealth of business experience having headed up his own business for 9 years. Mr Bean will add considerable value to the group, particularly in the finance and audit fields.

* Mr N Lamble as an independent non-executive director. Mr. Lamble has a BA degree, Higher Diploma in Education and completed his MBA in 1991. He has served as a director of the following companies: Corobrik Coastal, Steiner Services, First Garment Rental, Boston Laundries, Shield Security and Armtect Security. He has experience in strategic planning and restructuring of companies in different industries gained at the Bidvest and Tongaat groups. He occupied various managerial positions including experience structuring HR departments. Mr Lamble will add value in the business strategy, finance and HR areas of the group.
23 Oct 2008 13:15:34
(Official Notice)
Shareholders are advised that, in accordance with a resolution of the board of directors of the company, Hans Wessels will cease to act as a director with immediate effect.
16 Oct 2008 13:02:30
(Official Notice)
Further to the cautionary announcement issued by Imuniti on 2 September 2008, shareholders are advised that the company continues to be involved in negotiations which could have a material effect on the price of its shares. Shareholders are therefore advised to continue exercising caution in dealing with the shares of Imuniti until such time that a further announcement is made.
30 Sep 2008 15:43:03
(Official Notice)
Imuniti hereby advises that Mr Collin Matjila has resigned with immediate effect as a non- executive director and group chairperson as he did not extend his contractual term.
03 Sep 2008 17:32:07
(Official Notice)
Mr. J Graham has resigned as the company?s financial director and as the company?s secretary effective 30 September 2008. Imuniti has appointed Mr. M A Mantel to assume the role of financial director and as company secretary with effect from 1 October 2008.
02 Sep 2008 15:45:52
(Official Notice)
Shareholders are advised that the company is currently involved in negotiations which could have a material effect on the price of Imuniti's shares. Shareholders are therefore advised to exercise caution in dealing with the shares of Imuniti until such time that a further announcement is made.
29 Aug 2008 11:31:02
(Official Notice)
Shareholders are advised that at the AGM of the company held on 28 August 2008, all of the resolutions proposed, with the exception of resolution 5b, were approved by the requisite majority of votes. Resolution 5b, dealing with the re-election of Mr J Graham, was withdrawn as Mr J Graham is an executive director of the company who holds office as a director in terms of his conditions of employment. The special resolution passed will be submitted to CIPRO for registration.
27 Aug 2008 10:02:33
(Official Notice)
Further to the SENS announcements made on the 13 December 2007 and 28 May 2008, Imuniti advised that the long awaited medical trials of the Imuniti Wellness Pack have commenced. Imuniti has received confirmation from Dr. Gilbert Matsabisa of the Medical Research Council that phase one, being clinical safety trials on humans, has commenced.
07 Aug 2008 13:21:56
(Official Notice)
The company informs shareholders that the Annual Report has been posted to shareholders on, 7 August 2008.



Notice is hereby given that the second annual general meeting of the members of Imuniti will be held in Durban on 28 August 2008 at the Durban Country Club ,101 Walter Gilbert road at 16:00. Details of the proceedings, and resolutions, are contained in the aforementioned Annual Report.
24 Jul 2008 15:13:44
(Official Notice)
Imuniti is pleased to advise shareholders of the appointment of its CFO, Joe Graham, as the company secretary with immediate effect.
22 Jul 2008 11:26:47
(Official Notice)
Imuniti advised that Dr R L Bhoola has resigned as a non-executive director with effect from 22 July 2008
17 Jul 2008 12:25:35
(Official Notice)
Imuniti shareholders are advised that the company has raised R6 840 000 in capital by the issue of 100 000 000 ordinary shares at 6.84 cents per share. At the annual general meeting of the company held on 29 August 2007, the requisite majority of shareholders approved an ordinary resolution authorising the directors to issue shares for cash in accordance with the Listings Requirements of the JSE. As the issue of new shares represents a 13.03% increase in the issued ordinary share capital of the company, the following disclosure is required:

* 100 000 000 ordinary shares in the company have been issued at a price of 6.84 cents per ordinary share;

* The issue price of 6.84 cents per share represents the volume weighted average price at which Imuniti shares traded during the 30 day period up to and including 3 July 2008, being the date on which the issue price was agreed upon by the directors; and

* The shares have been issued to public shareholders as defined by the Listings Requirements.
02 Jun 2008 17:20:27
(Official Notice)
Imuniti to advised shareholders of the appointment of Dr. Ramesh Bhoola to the Board as an independent non-executive director.
28 May 2008 14:42:46
(C)
Sales have increased by 9.9 % as compared the fourteen month financial period ended 28 February 2007 to R69.6 million (R63.3 million). Gross Profit rose to R36.1 million (R31.4 million), but a net loss for the year attributable to ordinary shareholders of R15 million (profit of R2.4 million) was recorded. In addition, the headline loss per share came in at 1.15cps (profit of 0.41cps).



Dividend

No dividend has been declared.



Prospects

As reported with the release of the interim results, Imuniti has implemented new strategies. As can be seen from the second six month results these have started to show results. Imuniti started to achieve the turn around as reported. Imuniti focused on its core businesses, and has unlocked value out of its own range of products and brands. Imuniti operates in an area where the demand far exceeds the supply. The world is facing a food crisis, and with adequate capital the company will unlock further value for shareholders. As a manufacturer, Imuniti's strength and competitive advantage is that it owns two factories wherein lies its net asset value. Imuniti has increased market awareness of the group's products. This will be backed by lower operating expenses to ensure the sales translate into bottom line profits.
27 May 2008 16:53:30
(Official Notice)
Shareholders of Imuniti are advised that the directors of Imuniti expect a loss and headline loss per share for the year ended 29 February 2008 of approximately 1.99 cents and 1.15 cents respectively as compared to earnings and headline earnings per share of 0.42 cents and 0.41 cents respectively for the fourteen months ended 28 February 2007. The reviewed results for the financial year ended 29 February 2008 are expected to be published before the end of May 2008.
08 May 2008 14:11:50
(Official Notice)
Reference is made to an article that appeared in the Mail - Guardian dated 3 May 2008. Although the article did not directly attack Imuniti, the article was replete with factual inaccuracies. The board of Imuniti therefore feels that it is obliged to advise its shareholders that the content of the above article is spurious, that they take these allegations in the most serious light and will take the appropriate action to ensure that no further damage is done to the reputation of the company and its directors through false or misleading reports. The company is currently in a closed period and will publish results for the year ended 28 February 2008 before the end of May.
13 Mar 2008 14:55:13
(Official Notice)
Hugo Slabbert the current CFO is retiring at the end of March 2008, but will remain on the board as a non-executive director. Jonathan Rodger Graham has been appointed as a director. Jonathan is a Chartered Accountant who served his articles at BDO Spencer Steward and Deloitte.
19 Feb 2008 08:03:31
(Media Comment)
According to Business Report, Imuniti's empowerment partners, who have been accused of not delivering on their undertakings, have come out fighting and said that they would not dispose of their 34% stake in the company. Loselo Segwe, part of the BEE consortium, said that the empowerment partners have issued a court order to challenge misrepresentations that have being made against them.
05-Oct-2018
(X)
The Group is engaged in the manufacture, marketing and distribution of staple dry-food products, predominantly for the mass feeding market and lower income sectors of the market.


Send e-mail to for any enquiries or see Contact Details for phone numbers
Home   •   Terms & conditions   •   PAIA   •   Privacy Policy   •   Security Notice   •   Contact Details
Market Statistics are calculated by Sharenet and are therefore not the official JSE Market Statistics. The calculation/derivation may include underlying JSE data.
© 2018 SHARENET (PTY) Ltd, Cape Town, South Africa
Best in 800x600 with IE6 or Mozilla Firefox